B Cell Aberrance in Lupus: the Ringleader and the Solution
Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE...
Saved in:
| Published in | Clinical reviews in allergy & immunology Vol. 62; no. 2; pp. 301 - 323 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.04.2022
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE via both antibody-dependent and antibody-independent manners. Escape of autoreactive B cells from the central and peripheral tolerance checkpoints, over-activation of B cells and their excessive cytokines release which drive T cells and dendritic cells stimulation, and dysregulated surface molecules, as well as intracellular signal pathways involved in B cell biology, are all contributing to B cell aberrance and participating in the pathogenesis of SLE. Based on that rationale, targeting aberrance of B cells and relevant molecules and pathways is expected to be a promising strategy for lupus control. Multiple approaches targeting B cells through different mechanisms have been attempted, including B-cell depletion via monoclonal antibodies against B-cell-specific molecules, blockade of B-cell survival and activation factors, suppressing T-B crosstalk by interrupting costimulatory molecules and inhibiting intracellular activation signaling cascade by targeting pathway molecules in B cells. Though most attempts ended in failure, the efficacy of B-cell targeting has been encouraged by the FDA approval of belimumab that blocks B cell-activating factor (BAFF) and the recommended use of anti-CD20 as a remedial therapy in refractory lupus. Still, quantities of clinical trials targeting B cells or relevant molecules are ongoing and some of them have displayed promising preliminary results. Additionally, advances in multi-omics studies help deepen our understandings of B cell biology in lupus and may promote the discovery of novel potential therapeutic targets. The combination of real-world data with basic research achievements may pave the road to conquering lupus. |
|---|---|
| AbstractList | Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE via both antibody-dependent and antibody-independent manners. Escape of autoreactive B cells from the central and peripheral tolerance checkpoints, over-activation of B cells and their excessive cytokines release which drive T cells and dendritic cells stimulation, and dysregulated surface molecules, as well as intracellular signal pathways involved in B cell biology, are all contributing to B cell aberrance and participating in the pathogenesis of SLE. Based on that rationale, targeting aberrance of B cells and relevant molecules and pathways is expected to be a promising strategy for lupus control. Multiple approaches targeting B cells through different mechanisms have been attempted, including B-cell depletion via monoclonal antibodies against B-cell-specific molecules, blockade of B-cell survival and activation factors, suppressing T-B crosstalk by interrupting costimulatory molecules and inhibiting intracellular activation signaling cascade by targeting pathway molecules in B cells. Though most attempts ended in failure, the efficacy of B-cell targeting has been encouraged by the FDA approval of belimumab that blocks B cell-activating factor (BAFF) and the recommended use of anti-CD20 as a remedial therapy in refractory lupus. Still, quantities of clinical trials targeting B cells or relevant molecules are ongoing and some of them have displayed promising preliminary results. Additionally, advances in multi-omics studies help deepen our understandings of B cell biology in lupus and may promote the discovery of novel potential therapeutic targets. The combination of real-world data with basic research achievements may pave the road to conquering lupus. Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE via both antibody-dependent and antibody-independent manners. Escape of autoreactive B cells from the central and peripheral tolerance checkpoints, over-activation of B cells and their excessive cytokines release which drive T cells and dendritic cells stimulation, and dysregulated surface molecules, as well as intracellular signal pathways involved in B cell biology, are all contributing to B cell aberrance and participating in the pathogenesis of SLE. Based on that rationale, targeting aberrance of B cells and relevant molecules and pathways is expected to be a promising strategy for lupus control. Multiple approaches targeting B cells through different mechanisms have been attempted, including B-cell depletion via monoclonal antibodies against B-cell-specific molecules, blockade of B-cell survival and activation factors, suppressing T-B crosstalk by interrupting costimulatory molecules and inhibiting intracellular activation signaling cascade by targeting pathway molecules in B cells. Though most attempts ended in failure, the efficacy of B-cell targeting has been encouraged by the FDA approval of belimumab that blocks B cell-activating factor (BAFF) and the recommended use of anti-CD20 as a remedial therapy in refractory lupus. Still, quantities of clinical trials targeting B cells or relevant molecules are ongoing and some of them have displayed promising preliminary results. Additionally, advances in multi-omics studies help deepen our understandings of B cell biology in lupus and may promote the discovery of novel potential therapeutic targets. The combination of real-world data with basic research achievements may pave the road to conquering lupus. Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE via both antibody-dependent and antibody-independent manners. Escape of autoreactive B cells from the central and peripheral tolerance checkpoints, over-activation of B cells and their excessive cytokines release which drive T cells and dendritic cells stimulation, and dysregulated surface molecules, as well as intracellular signal pathways involved in B cell biology, are all contributing to B cell aberrance and participating in the pathogenesis of SLE. Based on that rationale, targeting aberrance of B cells and relevant molecules and pathways is expected to be a promising strategy for lupus control. Multiple approaches targeting B cells through different mechanisms have been attempted, including B-cell depletion via monoclonal antibodies against B-cell-specific molecules, blockade of B-cell survival and activation factors, suppressing T-B crosstalk by interrupting costimulatory molecules and inhibiting intracellular activation signaling cascade by targeting pathway molecules in B cells. Though most attempts ended in failure, the efficacy of B-cell targeting has been encouraged by the FDA approval of belimumab that blocks B cell-activating factor (BAFF) and the recommended use of anti-CD20 as a remedial therapy in refractory lupus. Still, quantities of clinical trials targeting B cells or relevant molecules are ongoing and some of them have displayed promising preliminary results. Additionally, advances in multi-omics studies help deepen our understandings of B cell biology in lupus and may promote the discovery of novel potential therapeutic targets. The combination of real-world data with basic research achievements may pave the road to conquering lupus.Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE via both antibody-dependent and antibody-independent manners. Escape of autoreactive B cells from the central and peripheral tolerance checkpoints, over-activation of B cells and their excessive cytokines release which drive T cells and dendritic cells stimulation, and dysregulated surface molecules, as well as intracellular signal pathways involved in B cell biology, are all contributing to B cell aberrance and participating in the pathogenesis of SLE. Based on that rationale, targeting aberrance of B cells and relevant molecules and pathways is expected to be a promising strategy for lupus control. Multiple approaches targeting B cells through different mechanisms have been attempted, including B-cell depletion via monoclonal antibodies against B-cell-specific molecules, blockade of B-cell survival and activation factors, suppressing T-B crosstalk by interrupting costimulatory molecules and inhibiting intracellular activation signaling cascade by targeting pathway molecules in B cells. Though most attempts ended in failure, the efficacy of B-cell targeting has been encouraged by the FDA approval of belimumab that blocks B cell-activating factor (BAFF) and the recommended use of anti-CD20 as a remedial therapy in refractory lupus. Still, quantities of clinical trials targeting B cells or relevant molecules are ongoing and some of them have displayed promising preliminary results. Additionally, advances in multi-omics studies help deepen our understandings of B cell biology in lupus and may promote the discovery of novel potential therapeutic targets. The combination of real-world data with basic research achievements may pave the road to conquering lupus. |
| Audience | Academic |
| Author | Nie, YuXue Zhang, Xuan Zhao, Lidan |
| Author_xml | – sequence: 1 givenname: YuXue surname: Nie fullname: Nie, YuXue organization: Department of Rheumatology and Clinical Immunology, The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Clinical Immunology Centre, Medical Epigenetics Research Centre, The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Difficult, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences – sequence: 2 givenname: Lidan surname: Zhao fullname: Zhao, Lidan email: zhaolidan@hotmail.com organization: Department of Rheumatology and Clinical Immunology, The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases – sequence: 3 givenname: Xuan orcidid: 0000-0001-8775-1699 surname: Zhang fullname: Zhang, Xuan email: zxpumch2003@sina.com organization: Clinical Immunology Centre, Medical Epigenetics Research Centre, The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Difficult, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33534064$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltr3DAQhUVJaS7tH-hDMRRKX5zqLjtv26U3WCj08ixkabyr4JW3kv3Qf9_Z7KZNQgkCaRi-czho5pycpDEBIS8ZvWSUmneFccp0TTmtadPgbZ6QM6ZUiy1tTu7Up-S8lGuKZCPaZ-RUCCUk1fKMXL2vljAM1aKDnF3yUMVUrebdXK6qaQPVt5jWA7gAuXIp3LS-j8M8xTE9J097NxR4cXwvyM-PH34sP9err5--LBer2ksjprpXBnrZCtnJhvU-UMecp33QITTKhFZrB6AZF4zRQLlSrlWd4TQ4rLToxAV5e_Dd5fHXDGWy21g8hnYJxrlYLhvNVMsUQ_T1A_R6nHPCdJZrxASXaPmXWrsBbEz9OGXn96Z2YSilSiolkLr8D4UnwDZ6nEQfsX9P8OaOYANumDbl-FflPvjqmHLuthDsLsety7_t7VQQaA6Az2MpGXrr4-T2PhghDpZRu18Ae1gAi2O1NwtgDUr5A-mt-6MicRAVhNMa8r9ve0T1Bxg_vFs |
| CitedBy_id | crossref_primary_10_1177_09612033241232053 crossref_primary_10_1016_j_autrev_2024_103640 crossref_primary_10_1016_j_jaut_2022_102871 crossref_primary_10_3389_fimmu_2022_855622 crossref_primary_10_1016_j_jaut_2022_102887 crossref_primary_10_1016_j_intimp_2025_114297 crossref_primary_10_1080_0886022X_2024_2395451 crossref_primary_10_1016_j_clim_2023_109778 crossref_primary_10_1097_BOR_0000000000000912 crossref_primary_10_1038_s41598_022_27310_8 crossref_primary_10_1080_0886022X_2024_2416605 crossref_primary_10_1016_j_jaut_2022_102890 crossref_primary_10_1007_s10238_023_01186_y crossref_primary_10_3390_genes12060931 crossref_primary_10_3390_ijms241511995 crossref_primary_10_1021_acsnano_2c05643 |
| Cites_doi | 10.1136/annrheumdis-2011-200937 10.1038/nri2602 10.1038/ng1673 10.1136/annrheumdis-2013-205067 10.1002/art.20980 10.1182/blood-2011-12-397919 10.1016/s1074-7613(02)00425-9 10.1186/ar3179 10.2147/jir.S67751 10.1111/j.1365-2567.2006.02433.x 10.1146/annurev-immunol-051116-052510 10.1002/eji.201444602 10.1016/j.addr.2018.12.005 10.1056/NEJMra071297 10.1038/ni.1667 10.1136/annrheumdis-2015-207653 10.1046/j.1365-3083.1999.00539.x 10.1186/s13075-015-0741-z 10.1136/ard.2007.075424 10.1084/jem.187.7.997 10.1056/NEJMoa1715519 10.3389/fimmu.2018.00427 10.1186/s13075-017-1441-7 10.1016/j.jaut.2013.01.008 10.1038/ni.1612 10.1111/j.1365-2249.1992.tb03042.x 10.1111/j.1600-065X.2007.00572.x 10.1186/ar4086 10.1038/ng.3496 10.1002/art.22197 10.1016/s0167-7799(97)01060-3 10.1007/s10875-010-9456-8 10.1191/096120398678919949 10.1146/annurev.immunol.15.1.203 10.1038/16717 10.1038/ni.1794 10.1038/nrrheum.2012.58 10.1038/35010115 10.1007/s11427-015-4953-x 10.1038/369340a0 10.1097/01.asn.0000014223.71109.13 10.1136/annrheumdis-2015-208140 10.1038/ni.3175 10.1111/j.1749-6632.2009.05132.x 10.1038/s41583-019-0233-2 10.1136/annrheumdis-2017-211631 10.1038/35040504 10.4161/epi.6.5.15374 10.1038/nri1886 10.1073/pnas.1001337107 10.1002/art.23673 10.1146/annurev.iy.10.040192.002043 10.1002/eji.200838138 10.1002/art.10856 10.1159/000045663 10.1016/j.immuni.2009.08.026 10.1136/annrheumdis-2012-202844 10.1016/s0065-2776(05)88001-0 10.1002/art.10264 10.1016/j.molimm.2014.01.009 10.1016/j.jaut.2019.102357 10.1182/blood-2004-11-4284 10.1136/annrheumdis-2013-205144 10.1038/ni1076 10.1136/annrheumdis-2020-217844 10.1172/jci45790 10.3390/ijms16047917 10.1093/hmg/ddi320 10.1084/jem.20151724 10.1084/jem.20051503 10.1136/annrheumdis-2015-207654 10.1111/j.1749-6632.2011.06347.x 10.1371/journal.pgen.1003336 10.1002/art.27233 10.1002/art.38037 10.1016/s1074-7613(03)00323-6 10.1016/j.clim.2020.108445 10.1073/pnas.0709205105 10.1080/1044667021000003961 10.1016/j.autrev.2015.07.013 10.1186/ar2506 10.1016/j.clim.2019.108272 10.1038/352532a0 10.1172/jci118924 10.1073/pnas.0807309106 10.1016/j.immuni.2007.12.004 10.1084/jem.20052033 10.1002/art.11313 10.1586/1744666x.2016.1152888 10.1056/nejm199805073381906 10.1038/nri1649 10.1084/jem.20051283 10.1038/s41423-019-0244-y 10.1084/jem.20170580 10.1038/ng.3603 10.1038/72162 10.1002/acr.21664 10.1038/nri3795 10.1007/s10067-010-1387-5 10.1038/jid.2008.240 10.1016/j.jaut.2020.102440 10.1016/s1074-7613(02)00295-9 10.1136/bmjopen-2018-025687 10.4049/immunohorizons.1700069 10.1016/j.jmb.2004.08.040 10.1056/NEJMoa2001180 10.3389/fimmu.2017.01986 10.1038/ni892 10.1136/ard.2007.073387 10.1038/ng1782 10.1160/th04-12-0774 10.1136/bmjopen-2019-032569 10.1016/s1074-7613(02)00397-7 10.1034/j.1399-0039.2003.00047.x 10.1172/jci117373 10.1038/383263a0 10.1016/j.cell.2009.08.041 10.3389/fimmu.2018.01957 10.1038/cmi.2017.133 10.1136/annrheumdis-2017-211388 10.1016/j.immuni.2008.05.009 10.1038/nrrheum.2014.33 10.1038/nrrheum.2009.184 10.1016/j.immuni.2015.04.010 10.1016/j.jaut.2019.102359 10.1182/blood-2007-09-110858 10.1093/rheumatology/ker176%JRheumatology 10.1002/art.38047 10.1038/ng.81 10.1002/art.24658 10.1016/s0092-8674(00)80373-6 10.3390/ijms151222342 10.1093/ckj/sfw022 10.1111/j.1365-2567.2009.03173.x 10.1136/ard.2008.098293 10.1038/334676a0 10.1136/annrheumdis-2012-201940 10.1136/ard.2006.060772 10.1038/s41467-018-04378-3 10.1038/nri2206 10.1016/s0092-8674(00)80337-2 10.1016/s0952-7915(00)00092-3 10.1038/cmi.2016.47 10.1111/imr.12733 10.1002/1529-0131(200106)44:6<1313::Aid-art223>3.0.Co;2-s 10.1080/08916930400002386 10.1002/art.22220 10.1002/art.34359 10.1002/jcph.1278 10.1016/j.molimm.2008.08.278 10.1111/j.1600-065X.2009.00782.x 10.1002/art.27601 10.1371/journal.pone.0041644 10.1146/annurev.immunol.26.021607.090316 10.1074/jbc.M309813200 10.1136/annrheumdis-2018-213032 10.1016/j.jaut.2016.06.001 10.1016/j.jaut.2009.11.001 10.1002/art.11354 10.1136/annrheumdis-2012-202760 10.1186/ar1942 10.1136/annrheumdis-2018-eular.5711 10.1073/pnas.0601539103 10.1084/jem.174.3.561 10.1006/clin.1997.4353 10.1002/art.10681 10.1016/s0092-8674(00)81692-x 10.1086/423790 10.1189/jlb.0603279 10.1172/jci19301 10.1073/pnas.0603912103 10.1126/science.1535455 10.4049/jimmunol.178.5.3272 10.4049/jimmunol.1301553 10.4049/jimmunol.177.8.5236 10.4049/jimmunol.174.4.1775 10.4049/jimmunol.1101602 10.1136/lupus-2019-lsm.98 10.4049/jimmunol.173.1.657 10.1126/scisignal.3134pe25 10.1126/science.286.5445.1735 10.1093/rheumatology/keu475 10.1016/s0140-6736(10)61354-2 10.1093/rheumatology/kex067 10.1093/rheumatology/ket129 10.4049/jimmunol.150.11.4715 10.1126/science.1105160 10.1136/annrheumdis-2017-eular.2364 10.4049/jimmunol.179.8.5099 10.1002/art.40479 10.1002/art.38260 10.4049/jimmunol.1202986 10.4049/jimmunol.179.7.4704 10.1002/art.39856 10.1002/art.38742 10.4049/jimmunol.172.7.4298 10.4049/jimmunol.0903888 10.4049/jimmunol.0902592 10.1128/microbiolspec.MDNA3-0037-2014 10.1002/art.40049 10.4049/jimmunol.177.11.7723 10.4049/jimmunol.168.1.9 10.4049/jimmunol.1601725 10.1126/scitranslmed.3009131 10.1126/science.285.5425.260 10.4049/jimmunol.1403034 10.1126/science.1086907 10.1093/rheumatology/keh724 10.1126/science.1073924 10.4161/mabs.28841 10.4049/jimmunol.1203525 10.1002/art.41466 10.1016/s0960-9822(07)00488-5 10.4049/jimmunol.168.12.5993 10.4049/jimmunol.1202115 10.1126/science.2356469 10.4049/jimmunol.178.6.3822 10.1016/j.clim.2004.05.010 10.4049/jimmunol.1102176 10.4049/jimmunol.152.5.2163 10.4049/jimmunol.146.5.1685 10.1002/art.40439 10.4049/jimmunol.154.9.4404 10.4049/jimmunol.173.9.5361 10.1126/science.7618087 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2021 2021. Springer Science+Business Media, LLC, part of Springer Nature. COPYRIGHT 2022 Springer Springer Science+Business Media, LLC, part of Springer Nature 2021. |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2021 – notice: 2021. Springer Science+Business Media, LLC, part of Springer Nature. – notice: COPYRIGHT 2022 Springer – notice: Springer Science+Business Media, LLC, part of Springer Nature 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7U9 7X7 7XB 88E 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s12016-020-08820-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Central Student MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1559-0267 |
| EndPage | 323 |
| ExternalDocumentID | A700054553 33534064 10_1007_s12016_020_08820_7 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81630044 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: Chinese Academy of Medical Science Innovation Fund for Medical Sciences grantid: CIFMS2017-I2M-3-011 – fundername: National Natural Science Foundation of China grantid: 81771763 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: Chinese Academy of Medical Science Innovation Fund for Medical Sciences grantid: CIFMS2016-12M-1-003 – fundername: Chinese Academy of Medical Science Innovation Fund for Medical Sciences grantid: CIFMS2017-12M-1-008 – fundername: Grant from Medical Epigenetics Research Center, Chinese Academy of Medical Sciences grantid: 2017PT31035 – fundername: National Natural Science Foundation of China grantid: 81788101 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: Chinese Academy of Medical Science Innovation Fund for Medical Sciences grantid: CIFMS2016-12M-1-008 – fundername: Beijing Capital Health Development Fund grantid: 2020-2-4019 – fundername: National Natural Science Foundation of China grantid: 81771763 – fundername: National Natural Science Foundation of China grantid: 81788101 – fundername: National Natural Science Foundation of China grantid: 81630044 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VX 0VY 1N0 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 40E 53G 5GY 5RE 5VS 6NX 78A 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HCIFZ HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IAO IHR IHW IJ- IKXTQ IMOTQ INH INR ITC IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV ROL RPX RSV S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z7W Z82 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB AEIIB PMFND 7T5 7U9 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c473t-f57ef4934b481fcd0a1ac0fd6dd857d966aee6123110d0255a95b720da5a963b3 |
| IEDL.DBID | 7X7 |
| ISSN | 1559-0267 1080-0549 |
| IngestDate | Fri Jul 11 11:04:47 EDT 2025 Fri Jul 25 12:14:49 EDT 2025 Tue Jun 17 22:09:26 EDT 2025 Tue Jun 10 21:04:05 EDT 2025 Thu May 22 21:24:13 EDT 2025 Mon Jul 21 06:04:16 EDT 2025 Tue Jul 01 04:05:10 EDT 2025 Thu Apr 24 23:11:53 EDT 2025 Fri Feb 21 02:46:46 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | B cell Systemic lupus erythematosus Pathogenesis Target therapy |
| Language | English |
| License | 2021. Springer Science+Business Media, LLC, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-f57ef4934b481fcd0a1ac0fd6dd857d966aee6123110d0255a95b720da5a963b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-8775-1699 |
| PMID | 33534064 |
| PQID | 2648632496 |
| PQPubID | 326352 |
| PageCount | 23 |
| ParticipantIDs | proquest_miscellaneous_2486159151 proquest_journals_2648632496 gale_infotracmisc_A700054553 gale_infotracacademiconefile_A700054553 gale_healthsolutions_A700054553 pubmed_primary_33534064 crossref_citationtrail_10_1007_s12016_020_08820_7 crossref_primary_10_1007_s12016_020_08820_7 springer_journals_10_1007_s12016_020_08820_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20220400 2022-04-00 2022-Apr 20220401 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 4 year: 2022 text: 20220400 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States – name: Totowa |
| PublicationTitle | Clinical reviews in allergy & immunology |
| PublicationTitleAbbrev | Clinic Rev Allerg Immunol |
| PublicationTitleAlternate | Clin Rev Allergy Immunol |
| PublicationYear | 2022 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | Kayagaki, Yan, Seshasayee, Wang, Lee, French, Grewal, Cochran, Gordon, Yin, Starovasnik, Dixit (CR51) 2002; 17 Sims, Ettinger, Shirota, Yarboro, Illei, Lipsky (CR39) 2005; 105 Jackson, Jacobs, Arkatkar, Dam, Scharping, Kolhatkar, Hou, Buckner, Rawlings (CR24) 2016; 213 CR162 CR161 Mina-Osorio, LaStant, Keirstead, Whittard, Ayala, Stefanova, Garrido, Dimaano, Hilton, Giron, Lau, Hang, Postelnek, Kim, Min, Patel, Woods, Ramanujam, DeMartino, Narula, Xu (CR208) 2013; 65 Melchers (CR3) 2005; 5 Teng, Bruce, Diamond, Furie, van Vollenhoven, Gordon, Groark, Henderson, Oldham, Tak (CR221) 2019; 9 Srinivasan, Sasaki, Calado, Zhang, Paik, DePinho, Kutok, Kearney, Otipoby, Rajewsky (CR107) 2009; 139 Lam, Kühn, Rajewsky (CR105) 1997; 90 Belnoue, Pihlgren, McGaha, Tougne, Rochat, Bossen, Schneider, Huard, Lambert, Siegrist (CR49) 2008; 111 von Boehmer, Melchers (CR14) 2010; 11 Shultz, Rajan, Greiner (CR109) 1997; 15 Bouaziz, Yanaba, Venturi, Wang, Tisch, Poe, Tedder (CR20) 2007; 104 Amin, Schlissel (CR125) 2008; 9 Zhang, Wang, Yuan, Sun, Liu, Huang, Hu, Wang, Li, Song, Chen, Zhou, Zhang (CR232) 2020 CR173 CR171 Tsai, Wu, Yu, Lu, Tsai (CR71) 2000; 85 CR170 Rovin, Furie, Latinis, Looney, Fervenza, Sanchez-Guerrero, Maciuca, Zhang, Garg, Brunetta, Appel (CR152) 2012; 64 CR166 Kalunian, Davis, Merrill, Totoritis, Wofsy (CR193) 2002; 46 Sabatino, Pröbstel, Zamvil (CR4) 2019; 20 CR167 Arkatkar, Du, Jacobs, Dam, Hou, Buckner, Rawlings, Jackson (CR67) 2017; 214 Furie, Leon, Thomas, Petri, Chu, Hislop, Martin, Scheinberg (CR185) 2015; 74 Craft (CR199) 2012; 8 Kitani, Hara, Hirose, Harigai, Suzuki, Kawakami, Kawaguchi, Hidaka, Kawagoe, Nakamura (CR66) 1992; 88 Furie, Rovin, Houssiau, Malvar, Teng, Contreras, Amoura, Yu, Mok, Santiago, Saxena, Green, Ji, Kleoudis, Burriss, Barnett, Roth (CR179) 2020; 383 Voynova, Mahmoud, Woods, Weisman, Ettinger, Braley-Mullen (CR59) 2018; 2 Cardiel, Tumlin, Furie, Wallace, Joh, Linnik (CR214) 2008; 58 Halverson, Torres, Pelanda (CR15) 2004; 5 Davis (CR33) 2009; 9 Jones, Muller, Dore, Ikeji, Caverly, Chowdhury, Isenberg, Gordon, Ehrenstein (CR220) 2019; 9 CR133 Webb, Merrill, Kelly, Sestak, Kaufman, Langefeld, Ziegler, Kimberly, Edberg, Ramsey-Goldman, Petri, Reveille, Alarcón, Vilá, Alarcón-Riquelme, James, Gilkeson, Jacob, Moser, Gaffney, Vyse, Nath, Lipsky, Harley, Sawalha (CR84) 2009; 60 CR132 Mysler, Spindler, Guzman, Bijl, Jayne, Furie, Houssiau, Drappa, Close, Maciuca, Rao, Shahdad, Brunetta (CR159) 2013; 65 Schatz, Oettinger, Schlissel (CR12) 1992; 10 Spolski, Leonard (CR74) 2008; 26 Sawalha, Kaufman, Kelly, Adler, Aberle, Kilpatrick, Wakeland, Li, Wandstrat, Karp, James, Merrill, Lipsky, Harley (CR83) 2008; 67 Muta, Kurosaki, Misulovin, Sanchez, Nussenzweig, Ravetch (CR95) 1994; 369 CR148 Manjarrez-Orduño, Quách, Sanz (CR6) 2009; 129 Gagneux, Cheriyan, Hurtado-Ziola, van der Linden, Anderson, McClure, Varki, Varki (CR89) 2003; 278 CR146 CR147 Bertsias, Tektonidou, Amoura, Aringer, Bajema, Berden, Boletis, Cervera, Dörner, Doria, Ferrario, Floege, Houssiau, Ioannidis, Isenberg, Kallenberg, Lightstone, Marks, Martini, Moroni, Neumann, Praga, Schneider, Starra, Tesar, Vasconcelos, van Vollenhoven, Zakharova, Haubitz, Gordon, Jayne, Boumpas (CR157) 2012; 71 CR145 Vang, Congia, Macis, Musumeci, Orrú, Zavattari, Nika, Tautz, Taskén, Cucca, Mustelin, Bottini (CR115) 2005; 37 Tedder (CR169) 2009; 5 Linnik, Hu, Heilbrunn, Strand, Hurley, Joh (CR215) 2005; 52 Chen, Wang, Ma, Luo, Edberg, Kimberly, Wu (CR101) 2006; 54 Murayama, Furusawa, Chiba, Yamaji, Tamura, Miyake (CR149) 2017; 19 Morris, Sheng, Zhang, Wang, Zhu, Tombleson, Chen, Cunninghame Graham, Bentham, Roberts, Chen, Zuo, Wang, Wen, Yang, Liu, Yang, Li, Huang, Yin, Yang, Rönnblom, Fürnrohr, Voll, Schett, Costedoat-Chalumeau, Gaffney, Lau, Zhang, Yang, Cui, Vyse (CR223) 2016; 48 CR116 CR114 Nurieva, Chung, Hwang, Yang, Kang, Ma, Wang, Watowich, Jetten, Tian, Dong (CR22) 2008; 29 CR111 Bekeredjian-Ding, Jego (CR136) 2009; 128 Hahn (CR210) 1998; 338 Butt, Chan, Bourne, Hermes, Nguyen, Statham, O'Reilly, Strasser, Price, Schofield, Christ, Basten, Ma, Tangye, Phan, Rao, Brink (CR36) 2015; 42 Stohl, Metyas, Tan, Cheema, Oamar, Xu, Roschke, Wu, Baker, Hilbert (CR53) 2003; 48 Yap, Lai (CR1) 2015; 16 Cheema, Roschke, Hilbert, Stohl (CR52) 2001; 44 Ono, Okada, Bolland, Yanagi, Kurosaki, Ravetch (CR97) 1997; 90 Sun, Molineros, Looger, Zhou, Kim, Okada, Ma, Qi, Kim-Howard, Motghare, Bhattarai, Adler, Bang, Lee, Kim, Kang, Suh, Chung, Park, Choe, Shim, Kochi, Suzuki, Kubo, Sumida, Yamamoto, Lee, Kim, Han, Dozmorov, Kaufman, Wren, Harley, Shen, Chua, Zhang, Bae, Nath (CR227) 2016; 48 CR118 Shlomchik (CR13) 2008; 28 Siriboonrit, Tsuchiya, Sirikong, Kyogoku, Bejrachandra, Suthipinittharm, Luangtrakool, Srinak, Thongpradit, Fujiwara, Chandanayingyong, Tokunaga (CR100) 2003; 61 Harley, Alarcón-Riquelme, Criswell, Jacob, Kimberly, Moser, Tsao, Vyse, Langefeld, Nath, Guthridge, Cobb, Mirel, Marion, Williams, Divers, Wang, Frank, Namjou, Gabriel, Lee, Gregersen, Behrens, Taylor, Fernando, Zidovetzki, Gaffney, Edberg, Rioux, Ojwang, James, Merrill, Gilkeson, Seldin, Yin, Baechler, Li, Wakeland, Bruner, Kaufman, Kelly (CR224) 2008; 40 Murray, Perry (CR153) 2010; 29 Menard, Saadoun, Isnardi, Ng, Meyers, Massad, Price, Abraham, Motaghedi, Buckner, Gregersen, Meffre (CR119) 2011; 121 Kawai, Andrews, Colvin, Sachs, Cosimi (CR194) 2000; 6 Kono, Kyogoku, Suzuki, Tsuchiya, Honda, Yamamoto, Tokunaga, Honda (CR110) 2005; 14 Halcomb, Musuka, Gutierrez, Wright, Satterthwaite (CR123) 2008; 46 Girschick, Grammer, Nanki, Vazquez, Lipsky (CR30) 2002; 46 CR120 Kil, de Bruijn, van Nimwegen, Corneth, van Hamburg, Dingjan, Thaiss, Rimmelzwaan, Elewaut, Delsing, van Loo, Hendriks (CR124) 2012; 119 Zhao, Liang, Wu, Li, Niu, Zhou, Wang, Chen, Zheng, Fei, Tang, Li, Zhang, He, Cao, Zhang (CR130) 2017; 14 Daridon, Blassfeld, Reiter, Mei, Giesecke, Goldenberg, Hansen, Hostmann, Frölich, Dörner (CR87) 2010; 12 CR128 CR129 Chen, Zheng, Su, Xu, Wang, Leng, Zhang, Li, Tang, Zhang, Zeng, Zhao, Zhang (CR154) 2011; 50 Langer, Ingersoll, Amirkhosravi, Meyer, Siddiqui, Ahmad, Walker, Amaya, Desai, Francis (CR195) 2005; 93 Liang, Gardner, Griswold, Bugelski, Song (CR70) 2006; 119 Hsu, Khare, Lee, Miner, Hu, Stolina, Hawkins, Chen, Ho, Min, Xiong, Boone, Zack (CR184) 2012; 30 Merrill, Burgos-Vargas, Westhovens, Chalmers, D'Cruz, Wallace, Bae, Sigal, Becker, Kelly, Raghupathi, Li, Peng, Kinaszczuk, Nash (CR204) 2010; 62 Daëron (CR93) 1997; 15 Tsubata, Honjo (CR108) 2000; 2 Anzelon, Wu, Rickert (CR131) 2003; 4 Chamberlain, Colman, Ranger, Burkly, Johnston, Otoul, Stach, Zamacona, Dörner, Urowitz, Hiepe (CR197) 2017; 76 Malkiel, Barlev, Atisha-Fregoso, Suurmond, Diamond (CR11) 2018; 9 CR218 CR219 Arce, Luger, Muehlinghaus, Cassese, Hauser, Horst, Lehnert, Odendahl, Hönemann, Heller, Kleinschmidt, Berek, Dörner, Krenn, Hiepe, Bargou, Radbruch, Manz (CR168) 2004; 75 Meffre (CR25) 2011; 1246 Radbruch, Muehlinghaus, Luger, Inamine, Smith, Dörner, Hiepe (CR10) 2006; 6 CR29 CR27 Aloui, Prigent, Sut, Tariket, Hamzeh-Cognasse, Pozzetto, Richard, Cognasse, Laradi, Garraud (CR56) 2014; 15 Kyogoku, Langefeld, Ortmann, Lee, Selby, Carlton, Chang, Ramos, Baechler, Batliwalla, Novitzke, Williams, Gillett, Rodine, Graham, Ardlie, Gaffney, Moser, Petri, Begovich, Gregersen, Behrens (CR117) 2004; 75 Folzenlogen, Hofer, Leung, Freed, Newell (CR41) 1997; 83 Kasaian, Whitters, Carter, Lowe, Jussif, Deng, Johnson, Witek, Senices, Konz, Wurster, Donaldson, Collins, Young, Grusby (CR75) 2002; 16 Torices, Gómez, Pannell (CR78) 2018; 9 CR104 CR21 CR103 Satterthwaite (CR121) 2017; 8 Zhao, Ye, Zhang (CR174) 2015; 58 Furie, Cash, Cronin, Katz, Weisman, Aranow, Liebling, Hudson, Berner, Coutts, de Haan (CR213) 2001; 28 CR106 Zhang, Shi, Xu, Chen, Lin, Zhang, Zeng, Zhang, Ba, He (CR61) 2012; 7 Vincent, Morand, Schneider, Mackay (CR187) 2014; 10 Grammer, Slota, Fischer, Gur, Girschick, Yarboro, Illei, Lipsky (CR42) 2003; 112 Viglianti, Lau, Hanley, Miko, Shlomchik, Marshak-Rothstein (CR137) 2003; 19 Li, Wu, Carter, Edberg, Su, Cooper, Kimberly (CR226) 2003; 48 Papadimitraki, Choulaki, Koutala, Bertsias, Tsatsanis, Gergianaki, Raptopoulou, Kritikos, Mamalaki, Sidiropoulos, Boumpas (CR139) 2006; 54 Condon, Ashby, Pepper, Cook, Levy, Griffith, Cairns, Lightstone (CR158) 2013; 72 CR38 Manetta, Bina, Ryan, Fox, Witcher, Kikly (CR181) 2014; 7 CR37 CR35 Ryffel, Car, Gunn, Roman, Hiestand, Mihatsch (CR68) 1994; 144 Tipton, Fucile, Darce, Chida, Ichikawa, Gregoretti, Schieferl, Hom, Jenks, Feldman, Mehr, Wei, Lee, Cheung, Rosenberg, Sanz (CR34) 2015; 16 Zouali (CR16) 2014; 62 Merrill, van Vollenhoven, Buyon, Furie, Stohl, Morgan-Cox, Dickson, Anderson, Lee, Berclaz, Dörner (CR183) 2016; 75 Hutcheson, Vanarsa, Bashmakov, Grewal, Sajitharan, Chang, Buggy, Zhou, Du, Satterthwaite, Mohan (CR207) 2012; 14 Shen, Fu, Deng, Qian, Zhao, Kaufman, Wu, Yu, Tang, Chen, Yang, Wong, Kawasaki, Tsuchiya, Sumida, Kawaguchi, Howe, Mok, Bang, Liu, Chang, Takasaki, Hashimoto, Harley, Guthridge, Grossman, Cantor, Song, Bae, Chen, Hahn, Lau, Tsao (CR143) 2010; 107 Dörner, Kaufmann, Wegener, Teoh, Goldenberg, Burmester (CR165) 2006; 8 Tamir, Dal Porto, Cambier (CR92) 2000; 12 Isenberg, Petri, Kalunian, Tanaka, Urowitz, Hoffman, Morgan-Cox, Iikuni, Silk, Wallace (CR182) 2016; 75 Boumpas, Furie, Manzi, Illei, Wallace, Balow, Vaishnaw (CR192) 2003; 48 Parrish-Novak, Dillon, Nelson, Hammond, Sprecher, Gross, Johnston, Madden, Xu, West, Schrader, Burkhead, Heipel, Brandt, Kuijper, Kramer, Conklin, Presnell, Berry, Shiota, Bort, Hambly, Mudri, Clegg, Moore, Grant, Lofton-Day, Gilbert, Rayond, Ching, Yao, Smith, Webster, Whitmore, Maurer, Kaushansky, Holly, Foster (CR73) 2000; 408 Wallweber, Compaan, Starovasnik, Hymowitz (CR48) 2004; 343 Wallace, Kalunian, Petri, Strand, Houssiau, Pike, Kilgallen, Bongardt, Barry, Kelley, Gordon (CR163) 2014; 73 CR47 Komura, Fujimoto, Yanaba, Matsushita, Matsushita, Horikawa, Ogawa, Shimizu, Hasegawa, Takehara, Sato (CR191) 2008; 67 Jeffries, Dozmorov, Tang, Merrill, Wren, Sawalha (CR228) 2011; 6 CR45 Lavie, Miceli-Richard, Ittah, Sellam, Gottenberg, Mariette (CR216) 2007; 66 RA Furie (8820_CR213) 2001; 28 YKO Teng (8820_CR221) 2019; 9 Y Deng (8820_CR144) 2013; 9 JA Gross (8820_CR46) 2000; 404 T Vang (8820_CR115) 2005; 37 DA Isenberg (8820_CR182) 2016; 75 WJ Zheng (8820_CR155) 2009; 68 S Subramanian (8820_CR142) 2006; 103 PS Linsley (8820_CR203) 1991; 174 LD Shultz (8820_CR109) 1997; 15 MD Catalina (8820_CR233) 2020; 110 L Ström (8820_CR57) 1999; 49 M Gonzalez (8820_CR112) 1998; 187 CC Goodnow (8820_CR18) 1991; 352 P Sinai (8820_CR32) 2014; 44 S Agrawal (8820_CR135) 2011; 31 S Arce (8820_CR168) 2004; 75 MH Cardiel (8820_CR214) 2008; 58 ME Munroe (8820_CR65) 2016; 75 C Daridon (8820_CR87) 2010; 12 N Shen (8820_CR143) 2010; 107 F Nimmerjahn (8820_CR98) 2008; 8 E Meffre (8820_CR25) 2011; 1246 8820_CR99 CC Goodnow (8820_CR17) 1988; 334 JT Merrill (8820_CR151) 2010; 62 J Hutcheson (8820_CR207) 2012; 14 MT Kasaian (8820_CR75) 2002; 16 MB Condon (8820_CR158) 2013; 72 BK Finck (8820_CR69) 1994; 94 G Murayama (8820_CR149) 2017; 19 TM Chan (8820_CR212) 2002; 13 T Tsubata (8820_CR108) 2000; 2 8820_CR91 8820_CR94 ZX Lian (8820_CR26) 2002; 9 X Li (8820_CR226) 2003; 48 TF Tedder (8820_CR90) 2005; 88 B Ryffel (8820_CR68) 1994; 144 HJ Wallweber (8820_CR48) 2004; 343 S Malkiel (8820_CR11) 2018; 9 C Kyogoku (8820_CR117) 2004; 75 JT Merrill (8820_CR186) 2018; 77 GP Sims (8820_CR39) 2005; 105 8820_CR86 8820_CR80 L Menard (8820_CR119) 2011; 121 8820_CR82 8820_CR201 W Stohl (8820_CR54) 2015; 17 8820_CR202 8820_CR205 J Manetta (8820_CR181) 2014; 7 8820_CR209 Y Cui (8820_CR222) 2013; 41 T Dörner (8820_CR164) 2015; 14 M Tsuiji (8820_CR28) 2006; 203 M Zouali (8820_CR16) 2014; 62 ED Papadimitraki (8820_CR139) 2006; 54 P Mina-Osorio (8820_CR208) 2013; 65 R Furie (8820_CR179) 2020; 383 F Melchers (8820_CR3) 2005; 5 E Belnoue (8820_CR49) 2008; 111 K Sakata (8820_CR150) 2018; 9 K Song (8820_CR113) 2020; 210 AC Grammer (8820_CR42) 2003; 112 R Spolski (8820_CR74) 2008; 26 BX Wu (8820_CR8) 2019; 16 DY Yap (8820_CR1) 2015; 16 SW Jackson (8820_CR24) 2016; 213 KP Lam (8820_CR105) 1997; 90 MA Jeffries (8820_CR228) 2011; 6 CY Tsai (8820_CR71) 2000; 85 JD Bouaziz (8820_CR20) 2007; 104 ML Haarhaus (8820_CR160) 2016; 9 JJ Sabatino (8820_CR4) 2019; 20 N Manjarrez-Orduño (8820_CR6) 2009; 129 MJ Shlomchik (8820_CR13) 2008; 28 D Butt (8820_CR36) 2015; 42 D Isenberg (8820_CR188) 2015; 74 JB Lefkowith (8820_CR211) 1996; 98 M Ono (8820_CR97) 1997; 90 ML Santiago-Raber (8820_CR141) 2010; 34 8820_CR104 8820_CR103 8820_CR106 AH Sawalha (8820_CR83) 2008; 67 FB Vincent (8820_CR187) 2014; 10 F Langer (8820_CR195) 2005; 93 J Parrish-Novak (8820_CR73) 2000; 408 BH Hahn (8820_CR210) 1998; 338 SL Nutt (8820_CR9) 2015; 15 R Brink (8820_CR31) 2018; 36 C Aloui (8820_CR56) 2014; 15 JY Chen (8820_CR101) 2006; 54 A Tumanov (8820_CR23) 2002; 17 8820_CR5 IL Weissman (8820_CR2) 2000; 100 8820_CR7 A Rahman (8820_CR43) 2008; 358 M Ono (8820_CR96) 1996; 383 F Zhang (8820_CR178) 2018; 77 8820_CR218 JT Merrill (8820_CR204) 2010; 62 AM Fairhurst (8820_CR140) 2008; 38 8820_CR219 R Lu (8820_CR64) 2016; 74 EF Mysler (8820_CR159) 2013; 65 JB Harley (8820_CR224) 2008; 40 CM Tipton (8820_CR34) 2015; 16 A Craxton (8820_CR50) 2005; 202 8820_CR37 8820_CR38 W Zhang (8820_CR61) 2012; 7 8820_CR35 8820_CR128 C Schwabe (8820_CR198) 2018; 58 8820_CR129 E Toubi (8820_CR63) 2004; 37 T Dörner (8820_CR165) 2006; 8 C Sun (8820_CR227) 2016; 48 8820_CR111 8820_CR27 8820_CR29 GA Viglianti (8820_CR137) 2003; 19 8820_CR114 8820_CR116 8820_CR118 HA Niederer (8820_CR172) 2010; 1183 T Arkatkar (8820_CR67) 2017; 214 JL Karnell (8820_CR58) 2019; 141 R Webb (8820_CR84) 2009; 60 H von Boehmer (8820_CR14) 2010; 11 LJ Crofford (8820_CR122) 2016; 12 DJ Wallace (8820_CR163) 2014; 73 M Wang (8820_CR134) 2020; 109 M Nakou (8820_CR85) 2013; 31 8820_CR21 LP Kil (8820_CR124) 2012; 119 8820_CR120 8820_CR146 8820_CR145 8820_CR148 8820_CR147 JA Bubier (8820_CR81) 2009; 106 JT Merrill (8820_CR183) 2016; 75 A Jones (8820_CR220) 2019; 9 M Daëron (8820_CR93) 1997; 15 8820_CR133 L Zhao (8820_CR174) 2015; 58 L Srinivasan (8820_CR107) 2009; 139 8820_CR132 GS Cheema (8820_CR52) 2001; 44 T Muta (8820_CR95) 1994; 369 TF Tedder (8820_CR169) 2009; 5 CM Syrett (8820_CR230) 2020; 107 R Lesley (8820_CR55) 2006; 103 I Bekeredjian-Ding (8820_CR136) 2009; 128 R Elgueta (8820_CR19) 2009; 229 AB Satterthwaite (8820_CR121) 2017; 8 AN Anzelon (8820_CR131) 2003; 4 R Halverson (8820_CR15) 2004; 5 K Komura (8820_CR191) 2008; 67 DL Morris (8820_CR223) 2016; 48 RF van Vollenhoven (8820_CR180) 2012; 71 C Aranow (8820_CR217) 2018; 77 M Mackay (8820_CR102) 2006; 203 8820_CR166 8820_CR167 8820_CR77 E Frangou (8820_CR88) 2020; 216 8820_CR79 HJ Girschick (8820_CR30) 2002; 46 DG Schatz (8820_CR12) 1992; 10 KC Kalunian (8820_CR193) 2002; 46 8820_CR171 8820_CR76 8820_CR170 8820_CR173 RR Graham (8820_CR225) 2006; 38 B Zhang (8820_CR232) 2020 8820_CR175 F Lavie (8820_CR216) 2007; 66 H Wu (8820_CR231) 2018; 15 A Kitani (8820_CR66) 1992; 88 KE Halcomb (8820_CR123) 2008; 46 H Chen (8820_CR154) 2011; 50 C Chamberlain (8820_CR197) 2017; 76 CS Tam (8820_CR206) 2018; 378 H Kono (8820_CR110) 2005; 14 R Furie (8820_CR44) 2008; 10 E Voynova (8820_CR59) 2018; 2 BH Rovin (8820_CR152) 2012; 64 H Hsu (8820_CR184) 2012; 30 8820_CR62 B Liang (8820_CR70) 2006; 119 DT Boumpas (8820_CR192) 2003; 48 8820_CR162 8820_CR161 8820_CR60 RA Furie (8820_CR185) 2015; 74 8820_CR189 R Herrera-Esparza (8820_CR72) 1998; 7 I Tamir (8820_CR92) 2000; 12 LD Zhao (8820_CR130) 2017; 14 Y Zhang (8820_CR229) 2019; 288 MD Linnik (8820_CR215) 2005; 52 A Hutloff (8820_CR200) 1999; 397 U Siriboonrit (8820_CR100) 2003; 61 D Folzenlogen (8820_CR41) 1997; 83 AM Krieg (8820_CR138) 2007; 220 8820_CR190 HS Dengler (8820_CR126) 2008; 9 BH Hahn (8820_CR156) 2012; 64 8820_CR196 8820_CR177 8820_CR176 R Torices (8820_CR78) 2018; 9 8820_CR45 8820_CR47 N Kayagaki (8820_CR51) 2002; 17 A Radbruch (8820_CR10) 2006; 6 GK Bertsias (8820_CR157) 2012; 71 CD Browne (8820_CR127) 2009; 31 W Stohl (8820_CR53) 2003; 48 P Gagneux (8820_CR89) 2003; 278 T Kawai (8820_CR194) 2000; 6 RI Nurieva (8820_CR22) 2008; 29 8820_CR40 JE Craft (8820_CR199) 2012; 8 DM Davis (8820_CR33) 2009; 9 E Murray (8820_CR153) 2010; 29 RH Amin (8820_CR125) 2008; 9 |
| References_xml | – ident: CR45 – ident: CR173 – volume: 71 start-page: 1343 issue: 8 year: 2012 end-page: 1349 ident: CR180 article-title: Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2011-200937 – ident: CR196 – volume: 9 start-page: 543 issue: 8 year: 2009 end-page: 555 ident: CR33 article-title: Mechanisms and functions for the duration of intercellular contacts made by lymphocytes publication-title: Nat Rev Immunol doi: 10.1038/nri2602 – volume: 37 start-page: 1317 issue: 12 year: 2005 end-page: 1319 ident: CR115 article-title: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant publication-title: Nat Genet doi: 10.1038/ng1673 – volume: 74 start-page: 2006 issue: 11 year: 2015 end-page: 2015 ident: CR188 article-title: Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205067 – volume: 52 start-page: 1129 issue: 4 year: 2005 end-page: 1137 ident: CR215 article-title: Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.20980 – volume: 119 start-page: 3744 issue: 16 year: 2012 end-page: 3756 ident: CR124 article-title: Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice publication-title: Blood doi: 10.1182/blood-2011-12-397919 – ident: CR80 – ident: CR201 – volume: 17 start-page: 515 issue: 4 year: 2002 end-page: 524 ident: CR51 article-title: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 publication-title: Immunity doi: 10.1016/s1074-7613(02)00425-9 – volume: 12 start-page: R204 issue: 6 year: 2010 ident: CR87 article-title: Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus publication-title: Arthritis Res Ther doi: 10.1186/ar3179 – ident: CR167 – volume: 7 start-page: 121 year: 2014 end-page: 131 ident: CR181 article-title: Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor publication-title: J Inflamm Res doi: 10.2147/jir.S67751 – volume: 119 start-page: 296 issue: 3 year: 2006 end-page: 305 ident: CR70 article-title: Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus publication-title: Immunology doi: 10.1111/j.1365-2567.2006.02433.x – volume: 36 start-page: 339 year: 2018 end-page: 357 ident: CR31 article-title: Self-reactive B cells in the germinal center reaction publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-051116-052510 – volume: 44 start-page: 3522 issue: 12 year: 2014 end-page: 3531 ident: CR32 article-title: T/B-cell interactions are more transient in response to weak stimuli in SLE-prone mice publication-title: Eur J Immunol doi: 10.1002/eji.201444602 – volume: 141 start-page: 92 year: 2019 end-page: 103 ident: CR58 article-title: Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2018.12.005 – ident: CR132 – ident: CR218 – ident: CR5 – volume: 358 start-page: 929 issue: 9 year: 2008 end-page: 939 ident: CR43 article-title: Systemic lupus erythematosus publication-title: N Engl J Med doi: 10.1056/NEJMra071297 – volume: 9 start-page: 1388 issue: 12 year: 2008 end-page: 1398 ident: CR126 article-title: Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation publication-title: Nat Immunol doi: 10.1038/ni.1667 – volume: 75 start-page: 323 issue: 2 year: 2016 end-page: 331 ident: CR182 article-title: Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207653 – volume: 49 start-page: 523 issue: 5 year: 1999 end-page: 532 ident: CR57 article-title: Characterization of CD40-dependent immunoglobulin class switching publication-title: Scand J Immunol doi: 10.1046/j.1365-3083.1999.00539.x – volume: 17 start-page: 215 issue: 1 year: 2015 ident: CR54 article-title: Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials publication-title: Arthritis Res Ther doi: 10.1186/s13075-015-0741-z – ident: CR91 – volume: 67 start-page: 458 issue: 4 year: 2008 end-page: 461 ident: CR83 article-title: Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.075424 – ident: CR190 – volume: 187 start-page: 997 issue: 7 year: 1998 end-page: 1007 ident: CR112 article-title: The sequential role of lymphotoxin and B cells in the development of splenic follicles publication-title: J Exp Med doi: 10.1084/jem.187.7.997 – volume: 378 start-page: 1211 issue: 13 year: 2018 end-page: 1223 ident: CR206 article-title: Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1715519 – volume: 9 start-page: 427 year: 2018 ident: CR11 article-title: Plasma cell differentiation pathways in systemic lupus erythematosus publication-title: Frontiers in immunology doi: 10.3389/fimmu.2018.00427 – ident: CR86 – volume: 19 start-page: 234 issue: 1 year: 2017 ident: CR149 article-title: Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus publication-title: Arthritis Res Ther doi: 10.1186/s13075-017-1441-7 – volume: 41 start-page: 25 year: 2013 end-page: 33 ident: CR222 article-title: Genetic susceptibility to SLE: recent progress from GWAS publication-title: J Autoimmun doi: 10.1016/j.jaut.2013.01.008 – ident: CR27 – volume: 9 start-page: 613 issue: 6 year: 2008 end-page: 622 ident: CR125 article-title: Foxo1 directly regulates the transcription of recombination-activating genes during B cell development publication-title: Nat Immunol doi: 10.1038/ni.1612 – volume: 88 start-page: 75 issue: 1 year: 1992 end-page: 83 ident: CR66 article-title: Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1992.tb03042.x – volume: 220 start-page: 251 year: 2007 end-page: 269 ident: CR138 article-title: Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2007.00572.x – volume: 14 start-page: R243 issue: 6 year: 2012 ident: CR207 article-title: Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus publication-title: Arthritis Ther doi: 10.1186/ar4086 – ident: CR103 – volume: 48 start-page: 323 issue: 3 year: 2016 end-page: 330 ident: CR227 article-title: High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry publication-title: Nat Genet doi: 10.1038/ng.3496 – volume: 54 start-page: 3601 issue: 11 year: 2006 end-page: 3611 ident: CR139 article-title: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process publication-title: Arthritis Rheum doi: 10.1002/art.22197 – volume: 15 start-page: 302 issue: 8 year: 1997 end-page: 307 ident: CR109 article-title: Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency publication-title: Trends Biotechnol doi: 10.1016/s0167-7799(97)01060-3 – volume: 31 start-page: 89 issue: 1 year: 2011 end-page: 98 ident: CR135 article-title: TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors publication-title: J Clin Immunol doi: 10.1007/s10875-010-9456-8 – ident: CR38 – volume: 7 start-page: 154 issue: 3 year: 1998 end-page: 158 ident: CR72 article-title: Renal expression of IL-6 and TNFalpha genes in lupus nephritis publication-title: Lupus doi: 10.1191/096120398678919949 – volume: 15 start-page: 203 year: 1997 end-page: 234 ident: CR93 article-title: Fc receptor biology publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.203 – volume: 397 start-page: 263 issue: 6716 year: 1999 end-page: 266 ident: CR200 article-title: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 publication-title: Nature doi: 10.1038/16717 – ident: CR162 – volume: 11 start-page: 14 issue: 1 year: 2010 end-page: 20 ident: CR14 article-title: Checkpoints in lymphocyte development and autoimmune disease publication-title: Nat Immunol doi: 10.1038/ni.1794 – ident: CR114 – volume: 8 start-page: 337 issue: 6 year: 2012 end-page: 347 ident: CR199 article-title: Follicular helper T cells in immunity and systemic autoimmunity publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2012.58 – volume: 404 start-page: 995 issue: 6781 year: 2000 end-page: 999 ident: CR46 article-title: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease publication-title: Nature doi: 10.1038/35010115 – volume: 58 start-page: 1111 issue: 11 year: 2015 end-page: 1125 ident: CR174 article-title: B cells biology in systemic lupus erythematosus-from bench to bedside publication-title: Sci China Life Sci doi: 10.1007/s11427-015-4953-x – volume: 369 start-page: 340 issue: 6478 year: 1994 ident: CR95 article-title: A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling publication-title: Nature doi: 10.1038/369340a0 – ident: CR202 – volume: 28 start-page: 257 issue: 2 year: 2001 end-page: 265 ident: CR213 article-title: Treatment of systemic lupus erythematosus with LJP 394 publication-title: J Rheum – ident: CR120 – volume: 13 start-page: 1219 issue: 5 year: 2002 end-page: 1229 ident: CR212 article-title: Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus publication-title: J Am Soc Nephrol: JASN doi: 10.1097/01.asn.0000014223.71109.13 – ident: CR145 – ident: CR148 – volume: 75 start-page: 2014 issue: 11 year: 2016 end-page: 2021 ident: CR65 article-title: Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208140 – ident: CR177 – volume: 16 start-page: 755 issue: 7 year: 2015 end-page: 765 ident: CR34 article-title: Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus publication-title: Nat Immunol doi: 10.1038/ni.3175 – volume: 1183 start-page: 69 year: 2010 end-page: 88 ident: CR172 article-title: FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.05132.x – volume: 20 start-page: 728 issue: 12 year: 2019 end-page: 745 ident: CR4 article-title: B cells in autoimmune and neurodegenerative central nervous system diseases publication-title: Nat Rev Neurosci doi: 10.1038/s41583-019-0233-2 – volume: 77 start-page: 355 issue: 3 year: 2018 end-page: 363 ident: CR178 article-title: A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211631 – volume: 408 start-page: 57 issue: 6808 year: 2000 end-page: 63 ident: CR73 article-title: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function publication-title: Nature doi: 10.1038/35040504 – ident: CR111 – ident: CR219 – volume: 6 start-page: 593 issue: 5 year: 2011 end-page: 601 ident: CR228 article-title: Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus publication-title: Epigenetics doi: 10.4161/epi.6.5.15374 – volume: 6 start-page: 741 issue: 10 year: 2006 end-page: 750 ident: CR10 article-title: Competence and competition: the challenge of becoming a long-lived plasma cell publication-title: Nat Rev Immunol doi: 10.1038/nri1886 – volume: 107 start-page: 15838 issue: 36 year: 2010 end-page: 15843 ident: CR143 article-title: Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1001337107 – volume: 58 start-page: 2470 issue: 8 year: 2008 end-page: 2480 ident: CR214 article-title: Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial publication-title: Arthritis Rheum doi: 10.1002/art.23673 – volume: 31 start-page: 172 issue: 2 year: 2013 end-page: 179 ident: CR85 article-title: Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells publication-title: Clin Exp Rheumatol – ident: CR21 – volume: 10 start-page: 359 year: 1992 end-page: 383 ident: CR12 article-title: V(D)J recombination: molecular biology and regulation publication-title: Annu Rev Immunol doi: 10.1146/annurev.iy.10.040192.002043 – volume: 38 start-page: 1971 issue: 7 year: 2008 end-page: 1978 ident: CR140 article-title: Yaa autoimmune phenotypes are conferred by overexpression of TLR7 publication-title: Eur J Immunol doi: 10.1002/eji.200838138 – volume: 48 start-page: 719 issue: 3 year: 2003 end-page: 727 ident: CR192 article-title: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis publication-title: Arthritis Rheum doi: 10.1002/art.10856 – volume: 144 start-page: 927 issue: 5 year: 1994 end-page: 937 ident: CR68 article-title: Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice publication-title: Am J Pathol – volume: 85 start-page: 207 issue: 3 year: 2000 end-page: 214 ident: CR71 article-title: Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis publication-title: Nephron doi: 10.1159/000045663 – ident: CR116 – volume: 31 start-page: 749 issue: 5 year: 2009 end-page: 760 ident: CR127 article-title: Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy publication-title: Immunity doi: 10.1016/j.immuni.2009.08.026 – volume: 2 start-page: 18 issue: 1 year: 2000 end-page: 25 ident: CR108 article-title: B cell tolerance and autoimmunity publication-title: R Immunogenet – ident: CR189 – volume: 72 start-page: 1280 issue: 8 year: 2013 end-page: 1286 ident: CR158 article-title: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-202844 – volume: 88 start-page: 1 year: 2005 end-page: 50 ident: CR90 article-title: CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction publication-title: Adv Immunol doi: 10.1016/s0065-2776(05)88001-0 – ident: CR99 – volume: 46 start-page: 1255 issue: 5 year: 2002 end-page: 1263 ident: CR30 article-title: Expression of recombination activating genes 1 and 2 in peripheral B cells of patients with systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.10264 – volume: 62 start-page: 315 issue: 2 year: 2014 end-page: 320 ident: CR16 article-title: Transcriptional and metabolic pre-B cell receptor-mediated checkpoints: implications for autoimmune diseases publication-title: Mol Immunol doi: 10.1016/j.molimm.2014.01.009 – volume: 107 start-page: 102357 year: 2020 ident: CR230 article-title: Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease publication-title: J Autoimmun doi: 10.1016/j.jaut.2019.102357 – ident: CR37 – volume: 105 start-page: 4390 issue: 11 year: 2005 end-page: 4398 ident: CR39 article-title: Identification and characterization of circulating human transitional B cells publication-title: Blood doi: 10.1182/blood-2004-11-4284 – ident: CR133 – ident: CR82 – volume: 74 start-page: 1667 issue: 9 year: 2015 end-page: 1675 ident: CR185 article-title: A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205144 – volume: 5 start-page: 645 issue: 6 year: 2004 end-page: 650 ident: CR15 article-title: Receptor editing is the main mechanism of B cell tolerance toward membrane antigens publication-title: Nat Immunol doi: 10.1038/ni1076 – year: 2020 ident: CR232 article-title: In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-217844 – volume: 121 start-page: 3635 issue: 9 year: 2011 end-page: 3644 ident: CR119 article-title: The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans publication-title: J Clin Investig doi: 10.1172/jci45790 – volume: 16 start-page: 7917 issue: 4 year: 2015 end-page: 7931 ident: CR1 article-title: Pathogenesis of renal disease in systemic lupus erythematosus–the role of autoantibodies and lymphocytes subset abnormalities publication-title: Int J Mol Sci doi: 10.3390/ijms16047917 – ident: CR104 – volume: 14 start-page: 2881 issue: 19 year: 2005 end-page: 2892 ident: CR110 article-title: FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling publication-title: Hum Mol Genet doi: 10.1093/hmg/ddi320 – volume: 213 start-page: 733 issue: 5 year: 2016 end-page: 750 ident: CR24 article-title: B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6 publication-title: J Exp Med doi: 10.1084/jem.20151724 – volume: 203 start-page: 2157 issue: 9 year: 2006 end-page: 2164 ident: CR102 article-title: Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE publication-title: J Exp Med doi: 10.1084/jem.20051503 – ident: CR161 – volume: 75 start-page: 332 issue: 2 year: 2016 end-page: 340 ident: CR183 article-title: Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207654 – volume: 1246 start-page: 1 year: 2011 end-page: 10 ident: CR25 article-title: The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2011.06347.x – volume: 9 start-page: e1003336 issue: 2 year: 2013 ident: CR144 article-title: MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus publication-title: PLoS Genet doi: 10.1371/journal.pgen.1003336 – volume: 62 start-page: 222 issue: 1 year: 2010 end-page: 233 ident: CR151 article-title: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial publication-title: Arthritis Rheum doi: 10.1002/art.27233 – volume: 65 start-page: 2368 issue: 9 year: 2013 end-page: 2379 ident: CR159 article-title: Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study publication-title: Arthritis Rheum doi: 10.1002/art.38037 – volume: 19 start-page: 837 issue: 6 year: 2003 end-page: 847 ident: CR137 article-title: Activation of autoreactive B cells by CpG dsDNA publication-title: Immunity doi: 10.1016/s1074-7613(03)00323-6 – volume: 216 start-page: 108445 year: 2020 ident: CR88 article-title: Update on the cellular and molecular aspects of lupus nephritis publication-title: Clin Immunol doi: 10.1016/j.clim.2020.108445 – volume: 104 start-page: 20878 issue: 52 year: 2007 end-page: 20883 ident: CR20 article-title: Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0709205105 – volume: 9 start-page: 35 issue: 1 year: 2002 end-page: 45 ident: CR26 article-title: Increased frequency of pre-pro B cells in the bone marrow of New Zealand Black (NZB) mice: implications for a developmental block in B cell differentiation publication-title: Dev Immunol doi: 10.1080/1044667021000003961 – volume: 14 start-page: 1079 issue: 12 year: 2015 end-page: 1086 ident: CR164 article-title: The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2015.07.013 – ident: CR7 – ident: CR76 – volume: 10 start-page: R109 issue: 5 year: 2008 ident: CR44 article-title: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus publication-title: Arthritis Res Ther doi: 10.1186/ar2506 – ident: CR166 – volume: 210 start-page: 108272 year: 2020 ident: CR113 article-title: An update on genetic susceptibility in lupus nephritis publication-title: Clin Immunol doi: 10.1016/j.clim.2019.108272 – volume: 352 start-page: 532 issue: 6335 year: 1991 end-page: 536 ident: CR18 article-title: Breakdown of self-tolerance in anergic B lymphocytes publication-title: Nature doi: 10.1038/352532a0 – volume: 98 start-page: 1373 issue: 6 year: 1996 end-page: 1380 ident: CR211 article-title: Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus publication-title: J Clin Investig doi: 10.1172/jci118924 – volume: 106 start-page: 1518 issue: 5 year: 2009 end-page: 1523 ident: CR81 article-title: A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0807309106 – ident: CR209 – volume: 28 start-page: 18 issue: 1 year: 2008 end-page: 28 ident: CR13 article-title: Sites and stages of autoreactive B cell activation and regulation publication-title: Immunity doi: 10.1016/j.immuni.2007.12.004 – volume: 203 start-page: 393 issue: 2 year: 2006 end-page: 400 ident: CR28 article-title: A checkpoint for autoreactivity in human IgM+ memory B cell development publication-title: J Exp Med doi: 10.1084/jem.20052033 – volume: 48 start-page: 3242 issue: 11 year: 2003 end-page: 3252 ident: CR226 article-title: A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling publication-title: Arthritis Rheum doi: 10.1002/art.11313 – volume: 12 start-page: 763 issue: 7 year: 2016 end-page: 773 ident: CR122 article-title: The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy publication-title: Expert Rev Clin Immunol doi: 10.1586/1744666x.2016.1152888 – volume: 338 start-page: 1359 issue: 19 year: 1998 end-page: 1368 ident: CR210 article-title: Antibodies to DNA publication-title: N Engl J Med doi: 10.1056/nejm199805073381906 – volume: 5 start-page: 578 issue: 7 year: 2005 end-page: 584 ident: CR3 article-title: The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire publication-title: Nat Rev Immunol doi: 10.1038/nri1649 – ident: CR77 – volume: 202 start-page: 1363 issue: 10 year: 2005 end-page: 1374 ident: CR50 article-title: BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway publication-title: J Exp Med doi: 10.1084/jem.20051283 – volume: 16 start-page: 724 issue: 8 year: 2019 end-page: 726 ident: CR8 article-title: CXCR4 and CXCR5 orchestrate dynamic germinal center reactions and may contribute to the pathogenesis of systemic lupus erythematosus publication-title: Cell Mol Immunol doi: 10.1038/s41423-019-0244-y – ident: CR106 – ident: CR129 – volume: 214 start-page: 3207 issue: 11 year: 2017 end-page: 3217 ident: CR67 article-title: B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity publication-title: J Exp Med doi: 10.1084/jem.20170580 – volume: 48 start-page: 940 issue: 8 year: 2016 end-page: 946 ident: CR223 article-title: Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus publication-title: Nat Genet doi: 10.1038/ng.3603 – volume: 6 start-page: 114 issue: 2 year: 2000 ident: CR194 article-title: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand publication-title: Nat Med doi: 10.1038/72162 – volume: 64 start-page: 797 issue: 6 year: 2012 end-page: 808 ident: CR156 article-title: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis publication-title: Arthritis Care Res doi: 10.1002/acr.21664 – volume: 15 start-page: 160 issue: 3 year: 2015 end-page: 171 ident: CR9 article-title: The generation of antibody-secreting plasma cells publication-title: Nat Rev Immunol doi: 10.1038/nri3795 – volume: 29 start-page: 707 issue: 7 year: 2010 end-page: 716 ident: CR153 article-title: Off-label use of rituximab in systemic lupus erythematosus: a systematic review publication-title: Clin Rheumatol doi: 10.1007/s10067-010-1387-5 – volume: 129 start-page: 278 issue: 2 year: 2009 end-page: 288 ident: CR6 article-title: B cells and immunological tolerance publication-title: J Invest Dermatol doi: 10.1038/jid.2008.240 – volume: 109 start-page: 102440 year: 2020 ident: CR134 article-title: Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development publication-title: J Autoimmun doi: 10.1016/j.jaut.2020.102440 – ident: CR170 – ident: CR60 – volume: 16 start-page: 559 issue: 4 year: 2002 end-page: 569 ident: CR75 article-title: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity publication-title: Immunity doi: 10.1016/s1074-7613(02)00295-9 – volume: 9 start-page: e025687 issue: 3 year: 2019 ident: CR221 article-title: Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol publication-title: BMJ open doi: 10.1136/bmjopen-2018-025687 – volume: 2 start-page: 54 issue: 1 year: 2018 end-page: 66 ident: CR59 article-title: Requirement for CD40/CD40L interactions for development of autoimmunity differs depending on specific checkpoint and costimulatory pathways publication-title: ImmunoHorizons doi: 10.4049/immunohorizons.1700069 – volume: 343 start-page: 283 issue: 2 year: 2004 end-page: 290 ident: CR48 article-title: The crystal structure of a proliferation-inducing ligand, APRIL publication-title: J Mol Biol doi: 10.1016/j.jmb.2004.08.040 – volume: 383 start-page: 1117 issue: 12 year: 2020 end-page: 1128 ident: CR179 article-title: Two-year, randomized, controlled trial of belimumab in lupus nephritis publication-title: N Engl J Med doi: 10.1056/NEJMoa2001180 – ident: CR147 – volume: 8 start-page: 1986 year: 2017 ident: CR121 article-title: Bruton’s tyrosine kinase, a component of B cell signaling pathways, has multiple roles in the pathogenesis of lupus publication-title: Front Immunol doi: 10.3389/fimmu.2017.01986 – volume: 4 start-page: 287 issue: 3 year: 2003 end-page: 294 ident: CR131 article-title: Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function publication-title: Nat Immunol doi: 10.1038/ni892 – volume: 67 start-page: 867 issue: 6 year: 2008 end-page: 872 ident: CR191 article-title: Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.073387 – volume: 38 start-page: 550 issue: 5 year: 2006 end-page: 555 ident: CR225 article-title: A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus publication-title: Nat Genet doi: 10.1038/ng1782 – ident: CR47 – volume: 93 start-page: 1137 issue: 6 year: 2005 end-page: 1146 ident: CR195 article-title: The role of CD40 in CD40L- and antibody-mediated platelet activation publication-title: Thromb Haemost doi: 10.1160/th04-12-0774 – volume: 9 start-page: e032569 issue: 12 year: 2019 ident: CR220 article-title: Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial publication-title: BMJ open doi: 10.1136/bmjopen-2019-032569 – volume: 17 start-page: 239 issue: 3 year: 2002 end-page: 250 ident: CR23 article-title: Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues publication-title: Immunity doi: 10.1016/s1074-7613(02)00397-7 – ident: CR171 – volume: 61 start-page: 374 issue: 5 year: 2003 end-page: 383 ident: CR100 article-title: Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais publication-title: Tissue Antigens doi: 10.1034/j.1399-0039.2003.00047.x – volume: 94 start-page: 585 issue: 2 year: 1994 end-page: 591 ident: CR69 article-title: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice publication-title: J Clin Investig doi: 10.1172/jci117373 – volume: 383 start-page: 263 issue: 6597 year: 1996 end-page: 266 ident: CR96 article-title: Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB publication-title: Nature doi: 10.1038/383263a0 – volume: 139 start-page: 573 issue: 3 year: 2009 end-page: 586 ident: CR107 article-title: PI3 kinase signals BCR-dependent mature B cell survival publication-title: Cell doi: 10.1016/j.cell.2009.08.041 – volume: 9 start-page: 1957 year: 2018 ident: CR150 article-title: Up-regulation of TLR7-mediated IFN-α production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus publication-title: Front Immunol doi: 10.3389/fimmu.2018.01957 – ident: CR94 – ident: CR176 – volume: 15 start-page: 676 issue: 7 year: 2018 end-page: 684 ident: CR231 article-title: Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity publication-title: Cell Mol Immunol doi: 10.1038/cmi.2017.133 – volume: 76 start-page: 1837 issue: 11 year: 2017 end-page: 1844 ident: CR197 article-title: Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211388 – volume: 29 start-page: 138 issue: 1 year: 2008 end-page: 149 ident: CR22 article-title: Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages publication-title: Immunity doi: 10.1016/j.immuni.2008.05.009 – volume: 10 start-page: 365 issue: 6 year: 2014 end-page: 373 ident: CR187 article-title: The BAFF/APRIL system in SLE pathogenesis publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2014.33 – volume: 5 start-page: 572 issue: 10 year: 2009 end-page: 577 ident: CR169 article-title: CD19: a promising B cell target for rheumatoid arthritis publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2009.184 – volume: 42 start-page: 890 issue: 5 year: 2015 end-page: 902 ident: CR36 article-title: FAS inactivation releases unconventional germinal center B cells that escape antigen control and drive IgE and autoantibody production publication-title: Immunity doi: 10.1016/j.immuni.2015.04.010 – volume: 110 start-page: 102359 year: 2020 ident: CR233 article-title: The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus publication-title: J Autoimmun doi: 10.1016/j.jaut.2019.102359 – volume: 111 start-page: 2755 issue: 5 year: 2008 end-page: 2764 ident: CR49 article-title: APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells publication-title: Blood doi: 10.1182/blood-2007-09-110858 – volume: 50 start-page: 1640 issue: 9 year: 2011 end-page: 1644 ident: CR154 article-title: Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study publication-title: Rheumatology doi: 10.1093/rheumatology/ker176%JRheumatology – ident: CR128 – volume: 65 start-page: 2380 issue: 9 year: 2013 end-page: 2391 ident: CR208 article-title: Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase publication-title: Arthritis Rheum doi: 10.1002/art.38047 – volume: 40 start-page: 204 issue: 2 year: 2008 end-page: 210 ident: CR224 article-title: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci publication-title: Nat Genet doi: 10.1038/ng.81 – volume: 60 start-page: 2402 issue: 8 year: 2009 end-page: 2407 ident: CR84 article-title: A polymorphism within IL21R confers risk for systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.24658 – volume: 90 start-page: 1073 issue: 6 year: 1997 end-page: 1083 ident: CR105 article-title: In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death publication-title: Cell doi: 10.1016/s0092-8674(00)80373-6 – volume: 30 start-page: 197 issue: 2 year: 2012 end-page: 201 ident: CR184 article-title: A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease publication-title: Clin Exp Rheumatol – volume: 15 start-page: 22342 issue: 12 year: 2014 end-page: 22364 ident: CR56 article-title: The signaling role of CD40 ligand in platelet biology and in platelet component transfusion publication-title: Int J Mol Sci doi: 10.3390/ijms151222342 – volume: 9 start-page: 552 issue: 4 year: 2016 end-page: 555 ident: CR160 article-title: Ofatumumab treatment in lupus nephritis patients publication-title: Clin Kidney J doi: 10.1093/ckj/sfw022 – ident: CR205 – volume: 128 start-page: 311 issue: 3 year: 2009 end-page: 323 ident: CR136 article-title: Toll-like receptors–sentries in the B-cell response publication-title: Immunology doi: 10.1111/j.1365-2567.2009.03173.x – volume: 68 start-page: 1077 issue: 6 year: 2009 end-page: 1078 ident: CR155 article-title: Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe? publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.098293 – volume: 334 start-page: 676 issue: 6184 year: 1988 end-page: 682 ident: CR17 article-title: Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice publication-title: Nature doi: 10.1038/334676a0 – volume: 71 start-page: 1771 issue: 11 year: 2012 end-page: 1782 ident: CR157 article-title: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-201940 – volume: 66 start-page: 700 issue: 5 year: 2007 end-page: 703 ident: CR216 article-title: Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.060772 – volume: 9 start-page: 2018 issue: 1 year: 2018 ident: CR78 article-title: Kin discrimination allows plants to modify investment towards pollinator attraction publication-title: Nat Commun doi: 10.1038/s41467-018-04378-3 – ident: CR35 – volume: 8 start-page: 34 issue: 1 year: 2008 end-page: 47 ident: CR98 article-title: Fcgamma receptors as regulators of immune responses publication-title: Nat Rev Immunol doi: 10.1038/nri2206 – ident: CR29 – volume: 90 start-page: 293 issue: 2 year: 1997 end-page: 301 ident: CR97 article-title: Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling publication-title: Cell doi: 10.1016/s0092-8674(00)80337-2 – volume: 12 start-page: 307 issue: 3 year: 2000 end-page: 315 ident: CR92 article-title: Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction publication-title: Curr Opin Immunol doi: 10.1016/s0952-7915(00)00092-3 – volume: 14 start-page: 842 issue: 10 year: 2017 end-page: 849 ident: CR130 article-title: Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus publication-title: Cell Mol Immunol doi: 10.1038/cmi.2016.47 – volume: 288 start-page: 75 issue: 1 year: 2019 end-page: 84 ident: CR229 article-title: Epigenetic regulation of B cell fate and function during an immune response publication-title: Immunol Rev doi: 10.1111/imr.12733 – volume: 44 start-page: 1313 issue: 6 year: 2001 end-page: 1319 ident: CR52 article-title: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200106)44:6<1313::Aid-art223>3.0.Co;2-s – volume: 37 start-page: 457 issue: 6–7 year: 2004 end-page: 464 ident: CR63 article-title: The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway publication-title: Autoimmunity doi: 10.1080/08916930400002386 – volume: 54 start-page: 3908 issue: 12 year: 2006 end-page: 3917 ident: CR101 article-title: Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients publication-title: Arthritis Rheum doi: 10.1002/art.22220 – volume: 64 start-page: 1215 issue: 4 year: 2012 end-page: 1226 ident: CR152 article-title: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study publication-title: Arthritis Rheum doi: 10.1002/art.34359 – volume: 58 start-page: 1566 issue: 12 year: 2018 end-page: 1577 ident: CR198 article-title: Safety, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 655064, an antagonistic anti-CD40 antibody, in healthy subjects: a potential novel treatment for autoimmune diseases publication-title: J Clin Pharmacol doi: 10.1002/jcph.1278 – volume: 46 start-page: 233 issue: 2 year: 2008 end-page: 241 ident: CR123 article-title: Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells publication-title: Mol Immunol doi: 10.1016/j.molimm.2008.08.278 – volume: 229 start-page: 152 issue: 1 year: 2009 end-page: 172 ident: CR19 article-title: Molecular mechanism and function of CD40/CD40L engagement in the immune system publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2009.00782.x – ident: CR175 – volume: 62 start-page: 3077 issue: 10 year: 2010 end-page: 3087 ident: CR204 article-title: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial publication-title: Arthritis Rheum doi: 10.1002/art.27601 – volume: 7 start-page: e41644 issue: 8 year: 2012 ident: CR61 article-title: Aberrant CD40-induced NF-κB activation in human lupus B lymphocytes publication-title: PLoS ONE doi: 10.1371/journal.pone.0041644 – volume: 26 start-page: 57 year: 2008 end-page: 79 ident: CR74 article-title: Interleukin-21: basic biology and implications for cancer and autoimmunity publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090316 – volume: 278 start-page: 48245 issue: 48 year: 2003 end-page: 48250 ident: CR89 article-title: Human-specific regulation of alpha 2–6-linked sialic acids publication-title: J Biol Chem doi: 10.1074/jbc.M309813200 – volume: 77 start-page: 883 issue: 6 year: 2018 end-page: 889 ident: CR186 article-title: Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213032 – ident: CR79 – volume: 74 start-page: 182 year: 2016 end-page: 193 ident: CR64 article-title: Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies publication-title: J Autoimmun doi: 10.1016/j.jaut.2016.06.001 – volume: 34 start-page: 339 issue: 4 year: 2010 end-page: 348 ident: CR141 article-title: Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.11.001 – ident: CR40 – volume: 48 start-page: 3475 issue: 12 year: 2003 end-page: 3486 ident: CR53 article-title: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations publication-title: Arthritis Rheum doi: 10.1002/art.11354 – ident: CR146 – volume: 73 start-page: 183 issue: 1 year: 2014 end-page: 190 ident: CR163 article-title: Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-202760 – volume: 8 start-page: R74 issue: 3 year: 2006 ident: CR165 article-title: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus publication-title: Arthritis Res Ther doi: 10.1186/ar1942 – volume: 77 start-page: 690 issue: Suppl 2 year: 2018 end-page: 690 ident: CR217 article-title: FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-eular.5711 – volume: 103 start-page: 10717 issue: 28 year: 2006 end-page: 10722 ident: CR55 article-title: Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.0601539103 – volume: 174 start-page: 561 issue: 3 year: 1991 end-page: 569 ident: CR203 article-title: CTLA-4 is a second receptor for the B cell activation antigen B7 publication-title: J Exp Med doi: 10.1084/jem.174.3.561 – volume: 83 start-page: 199 issue: 3 year: 1997 end-page: 204 ident: CR41 article-title: Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients publication-title: Clin Immunol Immunopathol doi: 10.1006/clin.1997.4353 – volume: 46 start-page: 3251 issue: 12 year: 2002 end-page: 3258 ident: CR193 article-title: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial publication-title: Arthritis Rheum doi: 10.1002/art.10681 – volume: 100 start-page: 157 issue: 1 year: 2000 end-page: 168 ident: CR2 article-title: Stem cells: units of development, units of regeneration, and units in evolution publication-title: Cell doi: 10.1016/s0092-8674(00)81692-x – volume: 75 start-page: 504 issue: 3 year: 2004 end-page: 507 ident: CR117 article-title: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE publication-title: Am J Hum Genet doi: 10.1086/423790 – volume: 75 start-page: 1022 issue: 6 year: 2004 end-page: 1028 ident: CR168 article-title: CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations publication-title: J Leukoc Biol doi: 10.1189/jlb.0603279 – ident: CR118 – volume: 112 start-page: 1506 issue: 10 year: 2003 end-page: 1520 ident: CR42 article-title: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions publication-title: J Clin Investig doi: 10.1172/jci19301 – volume: 103 start-page: 9970 issue: 26 year: 2006 end-page: 9975 ident: CR142 article-title: A Tlr7 translocation accelerates systemic autoimmunity in murine lupus publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0603912103 – ident: CR62 – volume: 369 start-page: 340 issue: 6478 year: 1994 ident: 8820_CR95 publication-title: Nature doi: 10.1038/369340a0 – volume: 119 start-page: 3744 issue: 16 year: 2012 ident: 8820_CR124 publication-title: Blood doi: 10.1182/blood-2011-12-397919 – volume: 358 start-page: 929 issue: 9 year: 2008 ident: 8820_CR43 publication-title: N Engl J Med doi: 10.1056/NEJMra071297 – volume: 38 start-page: 550 issue: 5 year: 2006 ident: 8820_CR225 publication-title: Nat Genet doi: 10.1038/ng1782 – volume: 129 start-page: 278 issue: 2 year: 2009 ident: 8820_CR6 publication-title: J Invest Dermatol doi: 10.1038/jid.2008.240 – volume: 9 start-page: 35 issue: 1 year: 2002 ident: 8820_CR26 publication-title: Dev Immunol doi: 10.1080/1044667021000003961 – volume: 54 start-page: 3601 issue: 11 year: 2006 ident: 8820_CR139 publication-title: Arthritis Rheum doi: 10.1002/art.22197 – volume: 12 start-page: 307 issue: 3 year: 2000 ident: 8820_CR92 publication-title: Curr Opin Immunol doi: 10.1016/s0952-7915(00)00092-3 – volume: 7 start-page: 154 issue: 3 year: 1998 ident: 8820_CR72 publication-title: Lupus doi: 10.1191/096120398678919949 – volume: 14 start-page: 2881 issue: 19 year: 2005 ident: 8820_CR110 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddi320 – volume: 105 start-page: 4390 issue: 11 year: 2005 ident: 8820_CR39 publication-title: Blood doi: 10.1182/blood-2004-11-4284 – ident: 8820_CR94 doi: 10.1126/science.1535455 – ident: 8820_CR103 doi: 10.4049/jimmunol.178.5.3272 – volume: 5 start-page: 645 issue: 6 year: 2004 ident: 8820_CR15 publication-title: Nat Immunol doi: 10.1038/ni1076 – ident: 8820_CR209 doi: 10.4049/jimmunol.1301553 – ident: 8820_CR76 doi: 10.4049/jimmunol.177.8.5236 – ident: 8820_CR104 doi: 10.4049/jimmunol.174.4.1775 – volume: 90 start-page: 1073 issue: 6 year: 1997 ident: 8820_CR105 publication-title: Cell doi: 10.1016/s0092-8674(00)80373-6 – volume: 64 start-page: 1215 issue: 4 year: 2012 ident: 8820_CR152 publication-title: Arthritis Rheum doi: 10.1002/art.34359 – volume: 30 start-page: 197 issue: 2 year: 2012 ident: 8820_CR184 publication-title: Clin Exp Rheumatol – ident: 8820_CR129 doi: 10.4049/jimmunol.1101602 – ident: 8820_CR171 doi: 10.1136/lupus-2019-lsm.98 – volume: 40 start-page: 204 issue: 2 year: 2008 ident: 8820_CR224 publication-title: Nat Genet doi: 10.1038/ng.81 – volume: 74 start-page: 1667 issue: 9 year: 2015 ident: 8820_CR185 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205144 – ident: 8820_CR77 doi: 10.4049/jimmunol.173.1.657 – volume: 50 start-page: 1640 issue: 9 year: 2011 ident: 8820_CR154 publication-title: Rheumatology doi: 10.1093/rheumatology/ker176%JRheumatology – volume: 174 start-page: 561 issue: 3 year: 1991 ident: 8820_CR203 publication-title: J Exp Med doi: 10.1084/jem.174.3.561 – volume: 75 start-page: 323 issue: 2 year: 2016 ident: 8820_CR182 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207653 – volume: 107 start-page: 102357 year: 2020 ident: 8820_CR230 publication-title: J Autoimmun doi: 10.1016/j.jaut.2019.102357 – volume: 75 start-page: 1022 issue: 6 year: 2004 ident: 8820_CR168 publication-title: J Leukoc Biol doi: 10.1189/jlb.0603279 – volume: 62 start-page: 315 issue: 2 year: 2014 ident: 8820_CR16 publication-title: Mol Immunol doi: 10.1016/j.molimm.2014.01.009 – volume: 104 start-page: 20878 issue: 52 year: 2007 ident: 8820_CR20 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0709205105 – volume: 31 start-page: 172 issue: 2 year: 2013 ident: 8820_CR85 publication-title: Clin Exp Rheumatol – ident: 8820_CR128 doi: 10.1126/scisignal.3134pe25 – volume: 378 start-page: 1211 issue: 13 year: 2018 ident: 8820_CR206 publication-title: N Engl J Med doi: 10.1056/NEJMoa1715519 – ident: 8820_CR27 doi: 10.1126/science.286.5445.1735 – volume: 229 start-page: 152 issue: 1 year: 2009 ident: 8820_CR19 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2009.00782.x – volume: 54 start-page: 3908 issue: 12 year: 2006 ident: 8820_CR101 publication-title: Arthritis Rheum doi: 10.1002/art.22220 – ident: 8820_CR161 doi: 10.1093/rheumatology/keu475 – volume: 8 start-page: 34 issue: 1 year: 2008 ident: 8820_CR98 publication-title: Nat Rev Immunol doi: 10.1038/nri2206 – volume: 106 start-page: 1518 issue: 5 year: 2009 ident: 8820_CR81 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0807309106 – ident: 8820_CR175 doi: 10.1016/s0140-6736(10)61354-2 – volume: 48 start-page: 719 issue: 3 year: 2003 ident: 8820_CR192 publication-title: Arthritis Rheum doi: 10.1002/art.10856 – ident: 8820_CR162 doi: 10.1093/rheumatology/kex067 – ident: 8820_CR166 doi: 10.1093/rheumatology/ket129 – volume: 220 start-page: 251 year: 2007 ident: 8820_CR138 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2007.00572.x – volume: 72 start-page: 1280 issue: 8 year: 2013 ident: 8820_CR158 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-202844 – ident: 8820_CR86 doi: 10.4049/jimmunol.150.11.4715 – volume: 110 start-page: 102359 year: 2020 ident: 8820_CR233 publication-title: J Autoimmun doi: 10.1016/j.jaut.2019.102359 – volume: 10 start-page: 359 year: 1992 ident: 8820_CR12 publication-title: Annu Rev Immunol doi: 10.1146/annurev.iy.10.040192.002043 – volume: 202 start-page: 1363 issue: 10 year: 2005 ident: 8820_CR50 publication-title: J Exp Med doi: 10.1084/jem.20051283 – volume: 67 start-page: 458 issue: 4 year: 2008 ident: 8820_CR83 publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.075424 – ident: 8820_CR99 doi: 10.1126/science.1105160 – volume: 15 start-page: 302 issue: 8 year: 1997 ident: 8820_CR109 publication-title: Trends Biotechnol doi: 10.1016/s0167-7799(97)01060-3 – volume: 7 start-page: e41644 issue: 8 year: 2012 ident: 8820_CR61 publication-title: PLoS ONE doi: 10.1371/journal.pone.0041644 – volume: 48 start-page: 3242 issue: 11 year: 2003 ident: 8820_CR226 publication-title: Arthritis Rheum doi: 10.1002/art.11313 – ident: 8820_CR219 doi: 10.1136/annrheumdis-2017-eular.2364 – volume: 31 start-page: 749 issue: 5 year: 2009 ident: 8820_CR127 publication-title: Immunity doi: 10.1016/j.immuni.2009.08.026 – volume: 8 start-page: 1986 year: 2017 ident: 8820_CR121 publication-title: Front Immunol doi: 10.3389/fimmu.2017.01986 – volume: 144 start-page: 927 issue: 5 year: 1994 ident: 8820_CR68 publication-title: Am J Pathol – ident: 8820_CR21 doi: 10.4049/jimmunol.179.8.5099 – volume: 9 start-page: e1003336 issue: 2 year: 2013 ident: 8820_CR144 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1003336 – volume: 62 start-page: 222 issue: 1 year: 2010 ident: 8820_CR151 publication-title: Arthritis Rheum doi: 10.1002/art.27233 – volume: 62 start-page: 3077 issue: 10 year: 2010 ident: 8820_CR204 publication-title: Arthritis Rheum doi: 10.1002/art.27601 – volume: 65 start-page: 2380 issue: 9 year: 2013 ident: 8820_CR208 publication-title: Arthritis Rheum doi: 10.1002/art.38047 – volume: 5 start-page: 572 issue: 10 year: 2009 ident: 8820_CR169 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2009.184 – volume: 343 start-page: 283 issue: 2 year: 2004 ident: 8820_CR48 publication-title: J Mol Biol doi: 10.1016/j.jmb.2004.08.040 – volume: 66 start-page: 700 issue: 5 year: 2007 ident: 8820_CR216 publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.060772 – volume: 88 start-page: 75 issue: 1 year: 1992 ident: 8820_CR66 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1992.tb03042.x – volume: 8 start-page: R74 issue: 3 year: 2006 ident: 8820_CR165 publication-title: Arthritis Res Ther doi: 10.1186/ar1942 – volume: 9 start-page: 552 issue: 4 year: 2016 ident: 8820_CR160 publication-title: Clin Kidney J doi: 10.1093/ckj/sfw022 – volume: 112 start-page: 1506 issue: 10 year: 2003 ident: 8820_CR42 publication-title: J Clin Investig doi: 10.1172/jci19301 – volume: 12 start-page: 763 issue: 7 year: 2016 ident: 8820_CR122 publication-title: Expert Rev Clin Immunol doi: 10.1586/1744666x.2016.1152888 – volume: 278 start-page: 48245 issue: 48 year: 2003 ident: 8820_CR89 publication-title: J Biol Chem doi: 10.1074/jbc.M309813200 – volume: 10 start-page: 365 issue: 6 year: 2014 ident: 8820_CR187 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2014.33 – ident: 8820_CR202 doi: 10.1002/art.40479 – volume: 74 start-page: 2006 issue: 11 year: 2015 ident: 8820_CR188 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205067 – volume: 60 start-page: 2402 issue: 8 year: 2009 ident: 8820_CR84 publication-title: Arthritis Rheum doi: 10.1002/art.24658 – ident: 8820_CR205 doi: 10.1002/art.38260 – volume: 19 start-page: 837 issue: 6 year: 2003 ident: 8820_CR137 publication-title: Immunity doi: 10.1016/s1074-7613(03)00323-6 – volume: 29 start-page: 707 issue: 7 year: 2010 ident: 8820_CR153 publication-title: Clin Rheumatol doi: 10.1007/s10067-010-1387-5 – ident: 8820_CR148 doi: 10.4049/jimmunol.1202986 – ident: 8820_CR114 doi: 10.4049/jimmunol.179.7.4704 – ident: 8820_CR167 doi: 10.1002/art.39856 – volume: 16 start-page: 755 issue: 7 year: 2015 ident: 8820_CR34 publication-title: Nat Immunol doi: 10.1038/ni.3175 – ident: 8820_CR40 doi: 10.1002/art.38742 – volume: 16 start-page: 724 issue: 8 year: 2019 ident: 8820_CR8 publication-title: Cell Mol Immunol doi: 10.1038/s41423-019-0244-y – volume: 42 start-page: 890 issue: 5 year: 2015 ident: 8820_CR36 publication-title: Immunity doi: 10.1016/j.immuni.2015.04.010 – ident: 8820_CR37 doi: 10.4049/jimmunol.172.7.4298 – volume: 6 start-page: 114 issue: 2 year: 2000 ident: 8820_CR194 publication-title: Nat Med doi: 10.1038/72162 – volume: 107 start-page: 15838 issue: 36 year: 2010 ident: 8820_CR143 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1001337107 – ident: 8820_CR196 doi: 10.4049/jimmunol.0903888 – ident: 8820_CR173 – ident: 8820_CR145 doi: 10.4049/jimmunol.0902592 – volume: 41 start-page: 25 year: 2013 ident: 8820_CR222 publication-title: J Autoimmun doi: 10.1016/j.jaut.2013.01.008 – ident: 8820_CR7 doi: 10.1128/microbiolspec.MDNA3-0037-2014 – volume: 9 start-page: 613 issue: 6 year: 2008 ident: 8820_CR125 publication-title: Nat Immunol doi: 10.1038/ni.1612 – ident: 8820_CR177 doi: 10.1002/art.40049 – volume: 6 start-page: 593 issue: 5 year: 2011 ident: 8820_CR228 publication-title: Epigenetics doi: 10.4161/epi.6.5.15374 – ident: 8820_CR120 doi: 10.4049/jimmunol.177.11.7723 – ident: 8820_CR190 – ident: 8820_CR62 doi: 10.4049/jimmunol.168.1.9 – volume: 17 start-page: 239 issue: 3 year: 2002 ident: 8820_CR23 publication-title: Immunity doi: 10.1016/s1074-7613(02)00397-7 – ident: 8820_CR79 doi: 10.4049/jimmunol.1601725 – volume: 88 start-page: 1 year: 2005 ident: 8820_CR90 publication-title: Adv Immunol doi: 10.1016/s0065-2776(05)88001-0 – volume: 74 start-page: 182 year: 2016 ident: 8820_CR64 publication-title: J Autoimmun doi: 10.1016/j.jaut.2016.06.001 – volume: 64 start-page: 797 issue: 6 year: 2012 ident: 8820_CR156 publication-title: Arthritis Care Res doi: 10.1002/acr.21664 – volume: 8 start-page: 337 issue: 6 year: 2012 ident: 8820_CR199 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2012.58 – volume: 203 start-page: 2157 issue: 9 year: 2006 ident: 8820_CR102 publication-title: J Exp Med doi: 10.1084/jem.20051503 – volume: 4 start-page: 287 issue: 3 year: 2003 ident: 8820_CR131 publication-title: Nat Immunol doi: 10.1038/ni892 – volume: 73 start-page: 183 issue: 1 year: 2014 ident: 8820_CR163 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-202760 – ident: 8820_CR133 doi: 10.1126/scitranslmed.3009131 – volume: 9 start-page: 2018 issue: 1 year: 2018 ident: 8820_CR78 publication-title: Nat Commun doi: 10.1038/s41467-018-04378-3 – volume: 216 start-page: 108445 year: 2020 ident: 8820_CR88 publication-title: Clin Immunol doi: 10.1016/j.clim.2020.108445 – volume: 103 start-page: 10717 issue: 28 year: 2006 ident: 8820_CR55 publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.0601539103 – volume: 334 start-page: 676 issue: 6184 year: 1988 ident: 8820_CR17 publication-title: Nature doi: 10.1038/334676a0 – volume: 14 start-page: 1079 issue: 12 year: 2015 ident: 8820_CR164 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2015.07.013 – volume: 16 start-page: 7917 issue: 4 year: 2015 ident: 8820_CR1 publication-title: Int J Mol Sci doi: 10.3390/ijms16047917 – volume: 338 start-page: 1359 issue: 19 year: 1998 ident: 8820_CR210 publication-title: N Engl J Med doi: 10.1056/nejm199805073381906 – volume: 58 start-page: 1566 issue: 12 year: 2018 ident: 8820_CR198 publication-title: J Clin Pharmacol doi: 10.1002/jcph.1278 – volume: 48 start-page: 3475 issue: 12 year: 2003 ident: 8820_CR53 publication-title: Arthritis Rheum doi: 10.1002/art.11354 – volume: 109 start-page: 102440 year: 2020 ident: 8820_CR134 publication-title: J Autoimmun doi: 10.1016/j.jaut.2020.102440 – ident: 8820_CR45 doi: 10.1126/science.285.5425.260 – ident: 8820_CR116 doi: 10.4049/jimmunol.1403034 – volume: 48 start-page: 323 issue: 3 year: 2016 ident: 8820_CR227 publication-title: Nat Genet doi: 10.1038/ng.3496 – volume: 61 start-page: 374 issue: 5 year: 2003 ident: 8820_CR100 publication-title: Tissue Antigens doi: 10.1034/j.1399-0039.2003.00047.x – ident: 8820_CR189 – ident: 8820_CR29 doi: 10.1126/science.1086907 – volume: 2 start-page: 18 issue: 1 year: 2000 ident: 8820_CR108 publication-title: R Immunogenet – volume: 17 start-page: 215 issue: 1 year: 2015 ident: 8820_CR54 publication-title: Arthritis Res Ther doi: 10.1186/s13075-015-0741-z – volume: 187 start-page: 997 issue: 7 year: 1998 ident: 8820_CR112 publication-title: J Exp Med doi: 10.1084/jem.187.7.997 – volume: 20 start-page: 728 issue: 12 year: 2019 ident: 8820_CR4 publication-title: Nat Rev Neurosci doi: 10.1038/s41583-019-0233-2 – volume: 75 start-page: 332 issue: 2 year: 2016 ident: 8820_CR183 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207654 – volume: 68 start-page: 1077 issue: 6 year: 2009 ident: 8820_CR155 publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.098293 – year: 2020 ident: 8820_CR232 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-217844 – ident: 8820_CR201 doi: 10.1093/rheumatology/keh724 – volume: 111 start-page: 2755 issue: 5 year: 2008 ident: 8820_CR49 publication-title: Blood doi: 10.1182/blood-2007-09-110858 – ident: 8820_CR35 doi: 10.1126/science.1073924 – volume: 26 start-page: 57 year: 2008 ident: 8820_CR74 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090316 – volume: 213 start-page: 733 issue: 5 year: 2016 ident: 8820_CR24 publication-title: J Exp Med doi: 10.1084/jem.20151724 – volume: 75 start-page: 504 issue: 3 year: 2004 ident: 8820_CR117 publication-title: Am J Hum Genet doi: 10.1086/423790 – volume: 9 start-page: e032569 issue: 12 year: 2019 ident: 8820_CR220 publication-title: BMJ open doi: 10.1136/bmjopen-2019-032569 – volume: 210 start-page: 108272 year: 2020 ident: 8820_CR113 publication-title: Clin Immunol doi: 10.1016/j.clim.2019.108272 – volume: 28 start-page: 18 issue: 1 year: 2008 ident: 8820_CR13 publication-title: Immunity doi: 10.1016/j.immuni.2007.12.004 – volume: 65 start-page: 2368 issue: 9 year: 2013 ident: 8820_CR159 publication-title: Arthritis Rheum doi: 10.1002/art.38037 – volume: 9 start-page: 543 issue: 8 year: 2009 ident: 8820_CR33 publication-title: Nat Rev Immunol doi: 10.1038/nri2602 – ident: 8820_CR170 doi: 10.4161/mabs.28841 – ident: 8820_CR147 doi: 10.4049/jimmunol.1203525 – ident: 8820_CR218 doi: 10.1002/art.41466 – volume: 77 start-page: 883 issue: 6 year: 2018 ident: 8820_CR186 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213032 – ident: 8820_CR132 doi: 10.1016/s0960-9822(07)00488-5 – volume: 11 start-page: 14 issue: 1 year: 2010 ident: 8820_CR14 publication-title: Nat Immunol doi: 10.1038/ni.1794 – volume: 34 start-page: 339 issue: 4 year: 2010 ident: 8820_CR141 publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.11.001 – volume: 10 start-page: R109 issue: 5 year: 2008 ident: 8820_CR44 publication-title: Arthritis Res Ther doi: 10.1186/ar2506 – volume: 15 start-page: 22342 issue: 12 year: 2014 ident: 8820_CR56 publication-title: Int J Mol Sci doi: 10.3390/ijms151222342 – volume: 121 start-page: 3635 issue: 9 year: 2011 ident: 8820_CR119 publication-title: J Clin Investig doi: 10.1172/jci45790 – volume: 52 start-page: 1129 issue: 4 year: 2005 ident: 8820_CR215 publication-title: Arthritis Rheum doi: 10.1002/art.20980 – volume: 44 start-page: 1313 issue: 6 year: 2001 ident: 8820_CR52 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200106)44:6<1313::Aid-art223>3.0.Co;2-s – ident: 8820_CR47 doi: 10.4049/jimmunol.168.12.5993 – volume: 75 start-page: 2014 issue: 11 year: 2016 ident: 8820_CR65 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208140 – volume: 100 start-page: 157 issue: 1 year: 2000 ident: 8820_CR2 publication-title: Cell doi: 10.1016/s0092-8674(00)81692-x – volume: 14 start-page: 842 issue: 10 year: 2017 ident: 8820_CR130 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2016.47 – ident: 8820_CR146 doi: 10.4049/jimmunol.1202115 – volume: 28 start-page: 257 issue: 2 year: 2001 ident: 8820_CR213 publication-title: J Rheum – volume: 85 start-page: 207 issue: 3 year: 2000 ident: 8820_CR71 publication-title: Nephron doi: 10.1159/000045663 – volume: 36 start-page: 339 year: 2018 ident: 8820_CR31 publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-051116-052510 – volume: 383 start-page: 263 issue: 6597 year: 1996 ident: 8820_CR96 publication-title: Nature doi: 10.1038/383263a0 – volume: 1183 start-page: 69 year: 2010 ident: 8820_CR172 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.05132.x – volume: 141 start-page: 92 year: 2019 ident: 8820_CR58 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2018.12.005 – volume: 37 start-page: 457 issue: 6–7 year: 2004 ident: 8820_CR63 publication-title: Autoimmunity doi: 10.1080/08916930400002386 – volume: 9 start-page: 1388 issue: 12 year: 2008 ident: 8820_CR126 publication-title: Nat Immunol doi: 10.1038/ni.1667 – ident: 8820_CR5 doi: 10.1126/science.2356469 – volume: 58 start-page: 1111 issue: 11 year: 2015 ident: 8820_CR174 publication-title: Sci China Life Sci doi: 10.1007/s11427-015-4953-x – volume: 6 start-page: 741 issue: 10 year: 2006 ident: 8820_CR10 publication-title: Nat Rev Immunol doi: 10.1038/nri1886 – ident: 8820_CR82 doi: 10.4049/jimmunol.178.6.3822 – volume: 13 start-page: 1219 issue: 5 year: 2002 ident: 8820_CR212 publication-title: J Am Soc Nephrol: JASN doi: 10.1097/01.asn.0000014223.71109.13 – volume: 7 start-page: 121 year: 2014 ident: 8820_CR181 publication-title: J Inflamm Res doi: 10.2147/jir.S67751 – volume: 19 start-page: 234 issue: 1 year: 2017 ident: 8820_CR149 publication-title: Arthritis Res Ther doi: 10.1186/s13075-017-1441-7 – volume: 76 start-page: 1837 issue: 11 year: 2017 ident: 8820_CR197 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211388 – volume: 77 start-page: 690 issue: Suppl 2 year: 2018 ident: 8820_CR217 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-eular.5711 – volume: 29 start-page: 138 issue: 1 year: 2008 ident: 8820_CR22 publication-title: Immunity doi: 10.1016/j.immuni.2008.05.009 – volume: 49 start-page: 523 issue: 5 year: 1999 ident: 8820_CR57 publication-title: Scand J Immunol doi: 10.1046/j.1365-3083.1999.00539.x – volume: 5 start-page: 578 issue: 7 year: 2005 ident: 8820_CR3 publication-title: Nat Rev Immunol doi: 10.1038/nri1649 – volume: 38 start-page: 1971 issue: 7 year: 2008 ident: 8820_CR140 publication-title: Eur J Immunol doi: 10.1002/eji.200838138 – volume: 103 start-page: 9970 issue: 26 year: 2006 ident: 8820_CR142 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0603912103 – volume: 31 start-page: 89 issue: 1 year: 2011 ident: 8820_CR135 publication-title: J Clin Immunol doi: 10.1007/s10875-010-9456-8 – volume: 383 start-page: 1117 issue: 12 year: 2020 ident: 8820_CR179 publication-title: N Engl J Med doi: 10.1056/NEJMoa2001180 – volume: 203 start-page: 393 issue: 2 year: 2006 ident: 8820_CR28 publication-title: J Exp Med doi: 10.1084/jem.20052033 – volume: 71 start-page: 1771 issue: 11 year: 2012 ident: 8820_CR157 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-201940 – ident: 8820_CR38 doi: 10.1016/j.clim.2004.05.010 – volume: 77 start-page: 355 issue: 3 year: 2018 ident: 8820_CR178 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211631 – volume: 16 start-page: 559 issue: 4 year: 2002 ident: 8820_CR75 publication-title: Immunity doi: 10.1016/s1074-7613(02)00295-9 – volume: 12 start-page: R204 issue: 6 year: 2010 ident: 8820_CR87 publication-title: Arthritis Res Ther doi: 10.1186/ar3179 – ident: 8820_CR118 doi: 10.4049/jimmunol.1102176 – ident: 8820_CR60 doi: 10.4049/jimmunol.152.5.2163 – volume: 48 start-page: 940 issue: 8 year: 2016 ident: 8820_CR223 publication-title: Nat Genet doi: 10.1038/ng.3603 – volume: 15 start-page: 676 issue: 7 year: 2018 ident: 8820_CR231 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2017.133 – ident: 8820_CR106 doi: 10.4049/jimmunol.146.5.1685 – volume: 408 start-page: 57 issue: 6808 year: 2000 ident: 8820_CR73 publication-title: Nature doi: 10.1038/35040504 – volume: 1246 start-page: 1 year: 2011 ident: 8820_CR25 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2011.06347.x – ident: 8820_CR176 doi: 10.1002/art.40439 – volume: 44 start-page: 3522 issue: 12 year: 2014 ident: 8820_CR32 publication-title: Eur J Immunol doi: 10.1002/eji.201444602 – volume: 214 start-page: 3207 issue: 11 year: 2017 ident: 8820_CR67 publication-title: J Exp Med doi: 10.1084/jem.20170580 – volume: 46 start-page: 233 issue: 2 year: 2008 ident: 8820_CR123 publication-title: Mol Immunol doi: 10.1016/j.molimm.2008.08.278 – volume: 9 start-page: 1957 year: 2018 ident: 8820_CR150 publication-title: Front Immunol doi: 10.3389/fimmu.2018.01957 – volume: 139 start-page: 573 issue: 3 year: 2009 ident: 8820_CR107 publication-title: Cell doi: 10.1016/j.cell.2009.08.041 – volume: 94 start-page: 585 issue: 2 year: 1994 ident: 8820_CR69 publication-title: J Clin Investig doi: 10.1172/jci117373 – volume: 128 start-page: 311 issue: 3 year: 2009 ident: 8820_CR136 publication-title: Immunology doi: 10.1111/j.1365-2567.2009.03173.x – volume: 397 start-page: 263 issue: 6716 year: 1999 ident: 8820_CR200 publication-title: Nature doi: 10.1038/16717 – volume: 9 start-page: e025687 issue: 3 year: 2019 ident: 8820_CR221 publication-title: BMJ open doi: 10.1136/bmjopen-2018-025687 – volume: 119 start-page: 296 issue: 3 year: 2006 ident: 8820_CR70 publication-title: Immunology doi: 10.1111/j.1365-2567.2006.02433.x – ident: 8820_CR111 doi: 10.4049/jimmunol.154.9.4404 – volume: 58 start-page: 2470 issue: 8 year: 2008 ident: 8820_CR214 publication-title: Arthritis Rheum doi: 10.1002/art.23673 – volume: 98 start-page: 1373 issue: 6 year: 1996 ident: 8820_CR211 publication-title: J Clin Investig doi: 10.1172/jci118924 – ident: 8820_CR80 doi: 10.4049/jimmunol.173.9.5361 – volume: 46 start-page: 3251 issue: 12 year: 2002 ident: 8820_CR193 publication-title: Arthritis Rheum doi: 10.1002/art.10681 – volume: 37 start-page: 1317 issue: 12 year: 2005 ident: 8820_CR115 publication-title: Nat Genet doi: 10.1038/ng1673 – volume: 17 start-page: 515 issue: 4 year: 2002 ident: 8820_CR51 publication-title: Immunity doi: 10.1016/s1074-7613(02)00425-9 – ident: 8820_CR91 doi: 10.1126/science.7618087 – volume: 67 start-page: 867 issue: 6 year: 2008 ident: 8820_CR191 publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.073387 – volume: 2 start-page: 54 issue: 1 year: 2018 ident: 8820_CR59 publication-title: ImmunoHorizons doi: 10.4049/immunohorizons.1700069 – volume: 352 start-page: 532 issue: 6335 year: 1991 ident: 8820_CR18 publication-title: Nature doi: 10.1038/352532a0 – volume: 93 start-page: 1137 issue: 6 year: 2005 ident: 8820_CR195 publication-title: Thromb Haemost doi: 10.1160/th04-12-0774 – volume: 71 start-page: 1343 issue: 8 year: 2012 ident: 8820_CR180 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2011-200937 – volume: 288 start-page: 75 issue: 1 year: 2019 ident: 8820_CR229 publication-title: Immunol Rev doi: 10.1111/imr.12733 – volume: 9 start-page: 427 year: 2018 ident: 8820_CR11 publication-title: Frontiers in immunology doi: 10.3389/fimmu.2018.00427 – volume: 15 start-page: 203 year: 1997 ident: 8820_CR93 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.203 – volume: 14 start-page: R243 issue: 6 year: 2012 ident: 8820_CR207 publication-title: Arthritis Ther doi: 10.1186/ar4086 – volume: 46 start-page: 1255 issue: 5 year: 2002 ident: 8820_CR30 publication-title: Arthritis Rheum doi: 10.1002/art.10264 – volume: 83 start-page: 199 issue: 3 year: 1997 ident: 8820_CR41 publication-title: Clin Immunol Immunopathol doi: 10.1006/clin.1997.4353 – volume: 404 start-page: 995 issue: 6781 year: 2000 ident: 8820_CR46 publication-title: Nature doi: 10.1038/35010115 – volume: 90 start-page: 293 issue: 2 year: 1997 ident: 8820_CR97 publication-title: Cell doi: 10.1016/s0092-8674(00)80337-2 – volume: 15 start-page: 160 issue: 3 year: 2015 ident: 8820_CR9 publication-title: Nat Rev Immunol doi: 10.1038/nri3795 |
| SSID | ssj0020839 |
| Score | 2.410068 |
| SecondaryResourceType | review_article |
| Snippet | Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 301 |
| SubjectTerms | Allergology Antibodies, Monoclonal - therapeutic use Autoantibodies Autoimmune diseases Autoimmunity B cells B-Lymphocytes Belimumab BLyS protein CD20 antigen Cell activation Cell survival Clinical trials Costimulator Cytokines Dendritic cells Drug approval FDA approval Humans Immunological tolerance Immunology Immunopathogenesis Immunotherapy Internal Medicine Intracellular Intracellular signalling Lupus Lupus Erythematosus, Systemic Lymphocytes B Lymphocytes T Medicine Medicine & Public Health Monoclonal antibodies Systemic lupus erythematosus T cells T-Lymphocytes Therapeutic targets |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED_8APFF_LY6tYLggxbWpUmWvU1RRNQHceBbSJoUhFHFbf-_d1nbOVHBt9JcUnLJ5X7X3AfAqfUSUQNTifC2m2Q-VYmRyiWsUKKTGkppTobiw6O4HWR3L_ylCgob1d7u9ZVkOKlnwW6oq8hhlvyvUG8lchGWOdru5Mg16PQbMwtBharCY37uN6eCvh_EXzTRt6vRoHFu1mGtgopxf7q2G7Dgy01Yeaguw7egdxlf-SESWP9B5TF8_FrG95P3yagXI6yLn3DUYfBUjk3pwqv6J9g2DG6un69uk6oUQpJnko2TgktfZIplNuumRe7aJjV5u3DCuS6XDm0W4z1lUkFt7shMMIpb2Wk7g0-CWbYDS-Vb6fcgLrgS3jHUjVQCXEjjjFBZ3hXS5qKwPoK05o7OqzzhVK5iqGcZjomjGjmqA0e1jOC86fM-zZLxJ_UxMV1PIz0bEdN9GRAk5yyCs0BBQobfzk0VK4AzoHRVc5StOUoUjny-uV5YXQnnSJNTH2WpVyKCk6aZepLDWenfJkiDJIj0EA9FsDvdEM3MGOMMcVAWwUW9Q2aD_z7t_f-RH8Bqh0ItgpdQC5bGHxN_iABobI_Cfv8EXh33jw priority: 102 providerName: Springer Nature |
| Title | B Cell Aberrance in Lupus: the Ringleader and the Solution |
| URI | https://link.springer.com/article/10.1007/s12016-020-08820-7 https://www.ncbi.nlm.nih.gov/pubmed/33534064 https://www.proquest.com/docview/2648632496 https://www.proquest.com/docview/2486159151 |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-2FsZeRvfttms9GOxhE4sjWYr6MtKSrmxrGWWB7ElIlgyD4GRN8v_3TpaTpdA-2Vgn2zqddD9J9wHwwQWFqIFrJoMbMBEKzazSnvFay35hKaQ5LRQvr-TFWHyflJO04bZIZpXdnBgnaj-raI_8C1liUWhxLb_O_zHKGkWnqymFxmPYpdBlJNVqsllwIbzQrYE9HfgKnZxmWtc51HxkfkvWXKgFmdpSTHen5__0050D06iHzvfgWQKQ-bDt8efwKDQv4MllOiJ_CSen-VmYIoELN5Q0I-R_m_znar5anOQI9vJrfOs02i_ntvHxUbc19grG56PfZxcsJUhglVB8yepShVpoLpwYFHXle7awVa_20vtBqTyuZGwIFF8FdbynxYPVpVP9nrd4J7njr2GnmTXhLeR1qWXwHDUmJQaXynortagGUrlK1i5kUHTcMVWKHk5JLKZmE_eYOGqQoyZy1KgMPq3rzNvYGQ9SHxPTTev_uR54ZqgirixLnsHHSEFDD79d2eRBgC2gIFZblIdblDhkqu3irmNNGrILsxGwDN6vi6kmmaE1YbZCGiRB_IcoKYM3rUCsW8Z5yREdiQw-dxKyefn9zd5_-F8O4GmfHC6irdAh7CxvVuEdwqClO4qyfgS7w29_fozwejq6-nWNT8f94S3aOwDF |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIQEviG8CgxkJxANYNHFi15MQGoOpY-0e0Cb1zXNsR0Kq0rK2QvxT_I3cOUlLJ7G3vUXJxYkvZ_9-ju8D4HUZFLIGobkMZZ_nIdXcKu25qLTMUkspzWmhODqRg7P827gYb8GfLhaG3Cq7OTFO1H7q6B_5B_LEotTiWn6a_eRUNYp2V7sSGo1ZHIffv3DJNv949AW_75ssO_x6ejDgbVUB7nIlFrwqVKhyLfIy76eV8z2bWtervPS-XyiP9N-GQElJEBg9MW6ri1JlPW_xSIpSYLs34CYCb48We2q8XuAhndGNQz9tMOe6DdJpQvUQacndl7zHEHW52gDCy3DwDx5e2qCNuHd4D-62hJXtNxZ2H7ZC_QBujdot-Yew95kdhAkKlOGCinQE9qNmw-VsOd9jSC7Zd2x1Ev2lma19PNX9insEZ9eiusewXU_r8BRYVWgZvECEpkLkUllvpc5dX6rSyaoMCaSddoxrs5VT0YyJWedZJo0a1KiJGjUqgXere2ZNro4rpXdJ6aaJN10NdLOvIo8tCpHA2yhBQx2f7WwbsYA9oKRZG5I7G5I4RN3m5e7DmnaKmJu1QSfwanWZ7iS3tzpMlyiDIsg3kZUl8KQxiFXPhCgEsrE8gfedhawb_3-3n139Lrtwe3A6Gprh0cnxc7iTUbBH9FPage3FxTK8QAq2KF9Gu2dwft0D7S_imDmb |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB_qFYov4rfRaiMoPmjoJZvs3hZE-nW0tj1KsdC3db8CwpE7e3eI_5p_nTPJJucV7FvfQjLZZCczO7_JzgfAO-MFogYmE-7NIMl9KhMtpEtYKXmWaippTo7i2YgfXeZfr4qrNfjT5sJQWGW7JtYLtZtY-ke-TZFYVFpc8u0yhEWcHwy_TH8m1EGKdlrbdhqNiJz437_QfZt9Pj7Ab_0-y4aH3_aPktBhILG5YPOkLIQvc8lykw_S0rq-TrXtl447NyiEQ1dAe08FStBIOkLfWhZGZH2n8Ygzw3Dce7AuyCvqwfre4ej8onP3ENzIJryftptzGVJ2msQ9tLsU_EuxZGiDE7FiFm8ah3-s443t2toKDh_CgwBf491G3h7Bmq8ew8ZZ2KB_Ajt78b4fI4Hx19Syw8c_qvh0MV3MdmKEmvEFjjquo6djXbn6VPtj7ilc3gnznkGvmlT-BcRlIbl3DO01tSXnQjvNZW4HXBjLS-MjSFvuKBtql1MLjbFaVl0mjirkqKo5qkQEH7t7pk3ljlupt4jpqsk-7dRe7Yoa1RYFi-BDTUGKj8-2OuQv4AyohNYK5eYKJSqsXb3cflgVFoyZWop3BG-7y3QnBcFVfrJAGiRB9IkYLYLnjUB0M2OsYIjN8gg-tRKyHPz_0355-7tswQYqmTo9Hp28gvsZZX7UQUub0JtfL_xrxGNz8yYIfgzf71rX_gJgMD82 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=B+Cell+Aberrance+in+Lupus%3A+the+Ringleader+and+the+Solution&rft.jtitle=Clinical+reviews+in+allergy+%26+immunology&rft.au=Nie+YuXue&rft.au=Zhao%2C+Lidan&rft.au=Zhang%2C+Xuan&rft.date=2022-04-01&rft.pub=Springer+Nature+B.V&rft.issn=1080-0549&rft.eissn=1559-0267&rft.volume=62&rft.issue=2&rft.spage=301&rft.epage=323&rft_id=info:doi/10.1007%2Fs12016-020-08820-7&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1559-0267&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1559-0267&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1559-0267&client=summon |